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1. INTRODUCTION 
 
Oral drug delivery has been known for decades as the most widely utilized route 
of administration among all the routes that have been employed for dosage forms. The 
reasons that the oral route achieved such popularity may be in part attributed to its ease 
of administration, belief that by oral administration of the drug is well absorbed. All the 
pharmaceutical products formulated for systemic delivery via the oral route of 
administration irrespective of the mode of delivery (immediate, sustained or controlled 
release) and the design of dosage forms (either solid dispersion or liquid) must be 
developed within the intrinsic characteristics of GI physiology,1 pharmacokinetics, 
pharmacodynamics and formulation design is essential to achieve a systemic approach to 
the successful development of an oral pharmaceutical dosage form. 
 
In recent years, scientists2 have focused their attention on the formulation of 
sustained release tablets. The task of developing sustained release tablets is 
accomplished by using a suitable hydrophilic polymer.3 
 
1.1. Tablets 
1.1.1. General Introduction  
What is tablet?  
 Tablets are solid preparations which contain a single dose of one or more active 
substances and usually obtained by compressing uniform volumes of particles. Tablets 
are intended for oral administration in which some are swallowed as whole, some are 
after being chewed, some are dissolved or dispersed in water before being administered 
and some are retained in the mouth where the active substance is liberated. Tablets are 
usually round, circular solid cylinders, the end surfaces of which are flat or convex and 
the edges of which may be beveled. Tablets may be coated. 
 
The particles consist of one or more active substances with or without excipients 
such as diluents, binders, disintegrating agents, glidants, lubricants, substances are 
capable of modifying the behavior of the tablet in the digestive tract, colouring matter 
authorized by the competent authority and flavoring substance. 
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1.1.2. Type and classes of tablets: - 
a. Oral tablets for ingestion 
• Compressed tablets  
• Multiple compressed tablets  
• Layered tablets 
• Compression-coated tablets 
• Repeat-action tablets 
• Delayed-action and enteric- coated tablets  
• Sugar and chocolate – coated tablets  
• Film coated tablets  
• Chewable tablets 
 
b. Tablets used in oral cavity 
• Buccal tablets    
• Sublingual tablets   
• Troches and lozenges   
• Dental cones  
 
c. Tablets administered by other routes   
• Implantation tablets  
• Vaginal tablets  
 
d. Tablets used to prepare solutions  
• Effervescent tablets  
• Dispensing tablets  
• Hypodermic tablets 
• Table t triturates  
 
1.1.3. Tablet can be prepared by the following method4 
a. Wet granulation  
b. Dry granulation (Slugging technique) 
c. Direct compression 
 
Introduction
Dept.	of	Pharmaceutics,	KMCH	College	of	Pharmacy	 	3	
 
Ideal characteristics of Table t dosage form 
It has its own identity, free of chips, cracks, discoloration and Contamination. It 
should have strength to withstand mechanical shocks encountered in its production, 
packaging, shipping and dispensing. It should have chemical and physical stability. 
 
1.1.4 .Comparison of major steps involved in the Tablet manufacturing methods 
Table .1 
Steps Wet granulation Dry granulation Direct compression 
Step 1 
Mixing / blending of API 
and adjuvants 
Mixing / blending of API 
and adjuvants 
Mixing / blending of 
API and adjuvants 
Step 2 
Preparation of binder 
solution 
Compression in to slugs 
 
Compression 
Step 3 
Massing of binder 
solution of step 2 with 
powder mixture step 1 
Size reduction of slugs 
and sieving 
Step 4 
Wet screening of damp 
masses 
Mixing of granules with 
Pharmaceutical aids 
Step 5 Drying of wet granules 
Compression Step 6 
Resifting of dried 
granules and blending 
i h h i l idStep 7 Compression 
 
1.1.5. Different Excipients used in the tablet Formulation5 
Excipients are inactive ingredients these are added in the formulation to influence 
the absorption and bioavailability problems and ensure the acceptability, 
physicochemical stability during the shelf life, uniformity of the composition and dosage.  
Commonly used Excipients are Diluents (Fillers), binders and granulating agents, 
disintegrants, lubricants, glidants, emulsifiers. Surfactants, dissolution enhancers, 
dissolution retardants, buffering agents, lubricants, glidants coating agents, colorings 
agents, sweetening agents etc. 
 
Diluents (Fillers) 
Diluents are commonly added in the formulation (table t and capsules) to produce 
the necessary bulk. Diluents may be organic or inorganic subatances.among organic 
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diluents carbohydrates are widely used e.g. starch, lactose, microcrystalline cellulose. 
The hydrophilic powders are very useful in promoting the dissolution of poorly water 
soluble drugs e.g.Dicalcium phosphate. 
 
Vehicles 
Vehicles or solvent system is major component of liquid oral parental. 3 major 
categories of vehicles are aqueous vehicle (water, syrup, etc), non aqueous water 
miscible vehicles (propylene glycol, and sorbitol) and non aqueous water immiscible 
vehicles (Vegetable oils). Bioavailability of drugs from vehicles depends to a large 
extent on its miscibility with biological fluids.  
 
Binders 
Binders hold the ingredients in a table t together. Binders ensure that tablets and 
granules can be formed with required mechanical strength, Binders are usually starches, 
sugars, cellulose or modified cellulose such as microcrystalline cellulose, hydroxypropyl 
cellulose, lactose, Solution binders are dissolved in a solvent (for example water or 
alcohol can be used in wet granulation processes). Examples include gelatin, cellulose, 
cellulose derivatives, polyvinylpyrrolidone, starch, sucrose and polyethylene glycol.  
 
Disintegrants 
Disintegrants expand and dissolve when wet causing the table t to break apart in 
the digestive tract, releasing the active ingredients for absorption. They ensure that when 
the table t is in contact with water, it rapidly breaks down into smaller fragments, thereby 
facilitating dissolution. Examples of disintegrants include: crosslinked polyvinyl 
pyrrolidone, sodium starch glycolate, crosslinked sodium carboxymethyl cellulose 
(crosscarmellose). 
 
Colouring agents 
Colours are added to improve the appearance of a formulation. Colour 
consistency is important as it allows easy identification of a medication.  
 
Glidants 
Glidants are used to promote powder flow by reducing interparticle friction and 
cohesion. These are used in combination with lubricants as they have no ability to reduce 
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die wall friction. Examples include Colloidal silicon dioxide, talc, and magnesium 
carbonate. 
 
Lubricants 
Lubricants prevent ingredients from clumping together and from sticking to the 
table t punches or capsule filling machine. Lubricants also ensure that table t formation 
and ejection can occur with low friction between the solid and die wall.Common 
minerals like talc or silica, and fats, e.g. vegetable  stearin, Magnesium stearate or Stearic 
acid are the most frequently used lubricants in tablets or hard gelatin capsules. 
 
Preservatives 
Preservatives used to prevent the microbial growth and external factors 
pharmaceutical formulations are e.g. antioxidants like vitamins, the amino acids 
(cysteine, methionine) 
 
Sweeteners 
Sweeteners are added to make the ingredients more palatable , especially in 
chewable tablets such as antacid or liquids like cough syrup. Therefore, tooth decay is 
sometimes associated with cough syrup abuse. Sugar can be used to disguise unpleasant 
tastes or smells. 
 
Flavours 
Flavours can be used to mask unpleasant tasting active ingredients and improve 
the likelihood that the patient will complete a course of medication. Flavourings may be 
natural (e.g. fruit extract) or artificial. -a bitter product - mint, cherry or anise may be 
used. 
 
Coatings 
Tablet coatings protect table t ingredients from deterioration by moisture in the 
air and make large or unpleasant-tasting tablets easier to swallow. For most coated 
tablets, a hydroxy propylmethylcellulose (HPMC) film coating is used which is free of 
sugar and potential allergens. Occasionally other coating materials are used, for example 
synthetic polymers, shellac, corn starch zein or other polysaccharides. 
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1.1.6. Drug-Excipient Interactions and their Effect on Absorptioion 
Excipients6 are traditionally thought of as inert but they can have a tremendous 
impact on the pharmacological availability of a drug substance when added to a 
formulation. The magnitude of this effect will depend on the characteristics of the drug 
and on the quantity and properties of the Excipients. Excipients have traditionally been 
classified according to the function they perform in a formulation, although many 
Excipients perform multiple functions. Diluents allow the formulation of a practically 
sized tablet and can form large proportion by weight of a formulate product when, for 
example, the active ingredients is very potent. (The physical characteristic of the diluents 
are important, for example, triamterene was shown to dissolve more rapidly when it was 
formulated with hydrophilic fillers such as lactose and starch as compared with insoluble 
diluents) . Disintegrates tend to swell when wetted and so are added to a formulation to 
facilitate the breakdown of the dosage form in to granules and powder particles. The 
newer disintegrates ,called super disintegrates ,cause an extremely rapid break up of a 
tablet owing their ability to swell to many times their original size .wicking and swelling 
were found to be the primary mechanism of action for tablet disintegrants,while other 
mechanisms ,such as deformation recovery , particle repulsion theory, heat of wetting 
and evolution of gas etc , may play a role in particular cases of tablet disintegration 
(Kanig and Rudnic ,1984). 
 
Co processing is defined as combining or more established Excipients by an 
appropriate process .co processing of Excipients could lead to formation of Excipients 
with superior properties compared with the simple physical mixture of their components  
or  with  individual components A large number of co processed diluents are 
commercially available. The representative examples are Ludipress , Cellactose , and 
starlac . the use of co processing is a totally unexplored avenue in disintegrants . The 
widely used super disintegrants  are sodium   starch  glycolate , crospovidone, and 
croscarmellose sodium. 
 
Wet granulation is a size enlargement process in which a liquid is used to achieve 
agglomeration of solid particles in a formulation. Agglomeration of solid particles in 
pharmaceutical  formulation improves their properties  for  tabletting by rendering the 
particles free flowing , non-segregatting and suitable for compression (Kristensen,1988) . 
High shear forces in high- speed  mixers are widely used in the pharmaceutical industry 
Introduction
Dept.	of	Pharmaceutics,	KMCH	College	of	Pharmacy	 	7	
 
for wet granulation.several studies have investigated granulation parameters in high-
shear mixers(Shaefer et al ., 1986; Wehrle et al.,1993;Shiraishi et al.,1944) . processing 
parameters were shown to affect the growth rate of granules in the high-shear wet 
granulation process.  
 
1.1.7. Different Methods for Table t Preparation 
Tablets are manufactured by wet granulation, Dry granulation or direct 
compression method. 
 
a. Wet Granulation 
Wet granulation is the process in which a liquid is added to a powder in a vessel 
equipped with any type of agitation that will produce agglomeration or granules. These 
granules after drying are compressed to form tablets. 
 
Advantages wet granulation methods  
• Suitable for moist and heat sensitive drugs. Robust process suitable for most   
compounds. 
• Imparts flow ability to a formation can reduce the elasticity problems. 
• Binding the drug with Excipients thus reducing segregation problem. 
 
Disadvantages of wet granulation methods 
• Stability may be major concern for moisture sensitive or thermo labile drugs.  
•    Any incompatibility between formulation components is aggravated.  
• Properties of granules formed may be affected by processing variables like     
viscosity of granulating solution. 
• The rate of addition of granulating solution. 
• Type of mixer used and duration of mixing. 
• Method and rate of dry and wet blending. 
 
b. Dry Granulation 
In this technique, there is no use of liquids. The process involves the formation of 
slugs. Then the slugs are screened or milled to produce granules. The granules formed 
are then compressed to form tablets. 
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Advantages of Dry Granulation process7 
• The variables faced in the processing of the granules can lead to significant table 
problems. 
• It is suitable for heat sensitive and moisture drugs. 
• It is suitable for poor flow drugs. Because particle size of the can be increased. 
 
Disadvantages of Dry Granulation process 
• Not suitable  for all compounds , Compared to other methods it is a slow process 
• Lack of moisture may give rise to static charges, which may lead to segregation . 
 
c. Direct compression 
The term direct compression is used to define the process by which tablets are 
compressed directly from powder blends of active ingredient and suitable  excipients, 
which will flow uniformly in the die cavity & forms a firm compact.  
 
Advantages of direct compression methods  
• Reduced processing time, less number of equipments used, less power       
consumption   and labor costs.  
• Fewer manufacturing steps and less process validation.  
• Elimination of heat and moisture, thus increasing the stability.  
• The suitability of the process for thermo labile and moisture sensitive API’s.  
• The chances of batch-to-batch variation are negligible, because the unit 
operations required for manufacturing processes is fewer.  
• Provides stability against the effect of aging which affects the dissolution rates. 
• Prime particle dissolution.  
• In case of directly compressed tablets after disintegration, each primary drug   
• Particle is liberated. While in the case of tablets prepared by compression of 
Granules, small drug particles with a larger surface area adhere together into   
larger Agglomerates; thus decreasing the surface area available for dissolution. 
 
Disadvantages of direct compression methods 
• High dose drugs having high bulk volume, poor compressibility and poor        
Flow ability is not suitable  for direct compression. 
• Many active ingredients are not compressible either in crystalline or amorphous    
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forms.  
• The choice of Excipients for direct compression is extremely critical. Direct      
Compression diluents and binders must possess both good compressibility and                
good flow ability.  
• Problems in the uniform distribution of low dose drugs.  
• Direct compression blends may lead to un blending because of difference in      
particle  Size or density of drug and Excipients. 
• Lack of moisture may give rise to static charges, which may lead to segregation.  
• Capping, lamination, splitting, or layering of tablets due to air entrapment.  
 
1.2. Dissolution 
Dissolution is the process by which a solid solute of only fair solubility characteristics 
enters into the solution (Abodu M et.al, 1989). As a fundamental phenomenon, it is controlled by 
an affinity between the solid and the medium. Suggested that the dissolution   rate is controlled 
by the rate of diffusion a very thin layer of saturated solution that forms instantaneously around 
the solid particle.  
1.2.1. Reasons for tablets dissolution8  
 In vitro dissolution testing of solid dosages form is important for numbers of 
reasons are   
• It guides the formulation and product development toward product optimization. 
Dissolution studies in the early stages of a product’s development allow.  
• Differentiation between formulations and correlations identified with in vivo 
bioavailability data. 
• The conduct of such testing from early product development through approval 
and commercial product ensures control of any variables of materials and process 
that could affect the dissolution and quality standards. 
• It is a requirement for regulatory approval of marketing for product registered 
with the FDA contains the in vitro dissolution data generally obtained from 
batches used in pivotal clinical and /or bioavailability studies conducted during 
product development. Once the specifications are established in an approved 
NDA, they become official (USP) specifications for all subsequent batches and 
bioequivalent products.  
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1.2.2. Application of In -Vitro Dissolution Studies     
Fig: 1 – Invitro Dissolution Studies  
  
 
1.2.3 .Factors affecting the Rate of Dissolution Relating to the Solid Dosage Form9 
a. Effect of formulation factors on table t dissolution rate 
The dissolution rate of a pure drug can be altered significantly when mixed 
with various adjutants during the manufacturing process of solid dosage forms. 
These adjutants are added to satisfy certain pharmaceutical functions such as diluents, 
dyes, binders, granulating agents, disintegrants and lubricants. 
 
b. Diluents & Disintegrants 
Increasing the starch content (most commonly using diluents from 5 to 20% 
resulted in a dramatic increase in the dissolution rate of Salicylic acid tablets. This 
was attributed to better disintegration. Later, Finholt suggested that the hydrophobic 
drug crystals acquire a surface layer of fine starch particles that imparts a 
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hydrophilic property to the granular formulation and thereby increase the effective 
surface area and hence the dissolution rate. 
 
c. Binders & Granulating Agents  
Differences in binders used for Tolbutamide tablets resulted in variable 
dissolution characteristics and differences in the hypoglycemic effect observed clinically. 
Wet granulation has been shown to improve dissolution rates of poorly soluble drugs by 
imparting hydrophilic properties to the surface of the granules. 
• Magnesium stearate, a hydrophobic - lubricant tends to retard the dissolution rate 
of Salicylic acid tablets, while a water soluble surface active lubricant, sodium 
lauryl sulphate, enhanced the dissolution. 
• Stearates like Aluminum stearate, Stearic acid and talc decrease the effective 
drug solvent interfacial area by changing the surface characteristics of the 
tablets which results in reducing its wet ability, prolonging its disintegration time.  
• The enhancing effect of sodium lauryl sulphate, on the other hand, was suggested to 
be due, in part, to an increase in the microenvironment pH surrounding the 
sparingly soluble weak acid and to increase wetting and better solvent penetration 
into the tablets and granules as a result of lowering the interfacial tension 
between the solid surface and the solvent. 
 
d. Effect of processing factors 
The many processing factor used in table t manufacturing greatly influence the 
dissolution rates of the active ingredients. The method of granulation as well as the 
compression force used in the letting process, all contributes to the dissolution rate 
characteristics of the final product. 
 
e. Method of granulation 
Granulation process, in general, enhances the dissolution rate of poorly soluble 
drugs. The use of fillers and diluents, such as starch, spray - dried lactose and 
Microcrystalline Cellulose, tend to  increases the hydrophilicity of the active 
ingredients and improve their dissolution characteristics. the wet granulation 
procedure was considered as a superior method compared to the dry double 
compression procedure. With the advent of newer tabletting machines and materials, it 
became more evident that the careful formulation and proper mixing sequence and 
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time of adding the several ingredients are the main criteria that affect the 
dissolution characteristics of the tablets and not the method or granulation process.    
 
1.2.4. Effects of test parameters on dissolution rate agitation   
The relationship between intensity of agitation and the rate of dissolution varies 
considerably according to the type of agitation used, the degree of laminar and turbulent 
flow in the system, the shape and design of the stirrer and physico-chemical properties of 
the lid. When a stirring device is used such as the basket, paddle, rotating filler etc, the 
speed (or) agitation generates a flow that continuously changes the liquid solid 
interface between the solvent and the drug in a way similar to the flow rate through 
dissolution apparatus. In order to prevent turbulence and sustain a reproducing 
laminar flow, which is essential to obtain reliable results, either the speed of 
agitation (or) the flow rate, depending on the type of apparatus employed, should be 
maintained at a relatively low level. 
The empirical relationship between the rate of dissolution and the intensity of 
agitation is 
K= a (N) b  ………………….. (1) 
Where  
N is the speed of agitation, K is the dissolution rate and a & b are constants 
Other factors that affect the correlation between agitation and dissolution rate 
include the density of the solid phase, the size and characteristics of the solid, 
the stirrer, the dissolution vessel and the of solution of the solute. 
 
a. Temperature  
Generally a temperature of 37° C is always maintained during the 
dissolution determinations. The effect of temperature variation of dissolution 
medium depends mainly on the temperature solubility curves of the drug and 
excipients in the formulation for a dissolved molecule. The diffusion co-efficient, 
D, is dependant upon the temperatures T, according to the stock's equation. 
D = KT (6π nr) ………………….. (2) 
Where  
K is the Boltzmann constant and, 6π nr is the stoke's force for a spherical 
molecule (n is the viscosity in cgs (or) poise units and, r is the radius of the molecule). 
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b. Dissolution medium 
The selection of proper fluid for dissolution testing depends largely on the 
solubility of the drug, as well as economy and practical reasons. Various medium used 
in Dissolutions are pH 1.2, 2.5, 4.5, 6.5, and 7.8 
 
c. Viscosity of the Medium 
In the case of diffusion controlled dissolution processes, it would be 
expected that the dissolution rate decreases with an increases in viscosity. In the 
case of interfacial controlled dissolution processes however, viscosity should have 
very little effect. The stokes Einstein equation describes the diffusion co-efficient D, 
as a function of viscosity. Brawn and Parrott showed that the dissolution rate of 
Benzoic acid was inversely proportional to the viscosity of the dissolution medium 
utilizing various concentrations of sucrose and methyl cellulose solutions.  
 
1.3. Modified Release11    
1.3.1. Definition   
Modified release dosage form having the time course and /or location of the 
drug release chosen to accomplish therapeutic or inconvenience objectives not offered 
by conventional dosage forms. Various types of Modified release products (mainly 
oral, but also transdermal, intra muscular, subcutaneous) 
 
1.3.2 .Modified release delivery systems may be divided into three categories 
1. Extended release dosage forms 
2. Delayed release dosage forms 
3. Targeted release dosage forms 
 
1. Extended release dosage forms 
The release starts immediately, but is slow, results two fold reduction in dosing   
frequency Extended release dosage forms further divided in to two types they are 
a. Prolonged dosage forms 
b. sustained release dosage forms  
 
a. Prolonged dosage forms 
Release the drug slowly, provides a drug continuous supply over an extended 
period. 
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b. sustained release dosage forms   
Delivers an initial (loading) dose immediately, the loading dose is followed by 
a slow and constant release.  
 
2. Delayed release dosage forms 
Releases a discrete portion at later time, although one portion can be released 
immediately. Delayed release dosage forms further divided in to two types they are 
 
a. Enteric coated tablet 
The enteric coating table t is stable  in stomach pH; it will dissolve in the 
higher pH of small intestine.  
 
b. Repeat action tablet 
The first dose is released immediately; the second dose is released later saves 
one administration. 
 
3. Targeted release dosage forms 
Releases drug at or near the intended physiologic site of action.     
Targeted release dosage forms release the drug by following steps 
• First order targeting 
           Drug is delivered to the capillary bed of the site of action.       
• Second order targeting 
           Drug is delivered to special cell type (tumor cells). 
• Third order targeting 
            Drug is delivered to intracellular space of the target cells.  
  
 
1.3. 3. Rationale of Sustained Drug Delivery12 
The basic rational for Sustained drug delivery is to alter the pharmacokinetic and 
pharmacodynamic of pharmacological active moieties by using novel drug delivery 
system or by modifying the molecular structure and physiological parameters inherent in 
the selected route of administration. It is desirable that the duration of drug action 
becomes more a dosing property of a rate controlled dosage form and less or not at all a 
property of the drug molecules inherent kinetics properties. Thus optional design of 
Introduction
Dept.	of	Pharmaceutics,	KMCH	College	of	Pharmacy	 	15	
 
controlled release systems necessitates a thorough understanding of the pharmacokinetics 
and pharmacodynamic of the drugs.13  
 
1.3.4. Ideal characteristic of the drug for the sustained release dosage form are 
• Drug should have a shorter half-life as drug with a longer half-life are 
inherently long acting drugs. 
• Drug should be absorbed from large portion of gastrointestinal tract, since    
absorption must occur through the gut. 
• Drug should be having a good solubility profile to be a good candidate for 
sustained   release dosage form. 
• Dose of the drug should not be too large, as a larger dose is to be 
incorporated into sustained release dosage form. 
 
1.3.5. Attributes of successful sustained release dosage form design14 
• The system should not be significantly sensitive to the physiological factors at the  
site of administration E.g. For oral systems, effect of pH, gastric motility, food                    
and   physical activity should be minimal. 
• The mechanism of drug delivery should be based on the physicochemical      
Characters of the dosage form, rather than on the environmental factors of the    
host. 
• The system should have a high degree of dispersion. 
• The system should be specific to the area or the organ of interest. 
•  It should be easy to use and should have physical and chemical stability.  
 
Fig.2 
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Potential advantage of sustained release dosage form15  
• Avoid patient’s compliance problem due to reduced frequency of dosing. 
• Blood level oscillation characteristics of multiple dosing of conventional dosage             
form are reduced because a more even blood level is maintained. 
• Employ a less total drug. 
• Minimize or eliminate local or systemic side effects. 
• Minimize drug accumulation with chronic dosing. 
• Obtained less potential of reduction in drug activity with chronic use. 
• Improved efficiency in treatment. 
• Cure or control condition more promptly. 
• Improved control of condition i.e. reduced fluctuation in drug level. 
• Improved bioavailability of some drugs. 
• Make a use of special effects, e.g. sustained release aspect for relief of arthritis by             
dosing before bedtime. 
• Overall, administrations of sustained release form enable increased reliability of             
therapy.  
Disadvantages of sustained release dosage forms 
• Possibility of dose dumping. 
• Reduce potential for accurate dose adjustment 
• Slow absorption may delay the onset of action. 
• Increased potential for fist pass metabolism. 
• Possible reduction in systemic availability. 
• Drug release period restricted to residence time in gastrointestinal tract. 
 
1.3.6. Factors governing the design of sustained release dosage form16  
Drug related factors                                
• Aqueous solubility and pka 
• Partition coefficient  
• Drug stability 
• Protein binding  
• Molecular size and diffusivity 
 
Biological factors 
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• Absorption 
• Distribution 
• Metabolism 
• Biological half life 
• Side effects and safety considerations 
• Dose size 
 
Physiological factors    
• Prolonged drug absorption  
• Variability in GI emptying and motility 
• GI blood flow 
 
Pharmacological factors 
• Changes in drug effect upon multiple dosing 
• Sensitizing /tolerance  
 
Pharmacokinetic factors 
• Dose dumping  
• First pass metabolism 
• Variability of urinary pH effect on elimination  
• Enzyme induction /inhibition upon multiple dosing  
 
1.4 .Classification of oral controlled release system17 
a. Continuous release systems  
1. Dissolution controlled release systems  
 a. Matrix type             b. Reservoir type 
2. Diffusion controlled release systems 
 a. Matrix type             b. Reservoir type 
3. Dissolution and diffusion controlled release systems 
4. Ion exchange resin drug complexes 
5. Slow dissolving salts and complexes 
6. pH dependent formulations 
7. Osmotic pressure controlled systems  
8. Hydrodynamic pressure controlled systems 
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b. Delayed transit and continuous release systems  
1. Altered density systems 
a. High density 
b. Low density 
c. Floating 
2. Mucoadhesive systems 
3. Size based systems  
 
c. Delayed release systems 
1. Intestinal release systems 
2. Colonic release systems 
 
1.4.1. Dissolution controlled release systems 
Matrix tablets generally formulated by Embedded in a slowly dissolving or 
erodible matrix. Encapsulation or coating with slowly dissolving or erodible matrix 
substances. 
 
1.4.2. Dissolution control formulations are categories as  
a. Matrix dissolution control systems 
b. Encapsulation or reservoir dissolution control systems 
 
a. Matrix dissolution control systems   
  The matrix tablets are most often used for a drug-controlled release from a 
pharmaceutical dosage form.  In this system for delay and control of the release of the 
Drug that is dissolved or dispersed throughout a rate controlling medium. They are very 
common used materials are Hydrophilic matrixes, Fat waxes, and Plastic matrixes. 
Which control drug dissolution by controlling rate of dissolution fluid penetration into 
the matrix by altering the porosity of table t, decreasing wettability by it self getting 
dissolved at a slower rate. The drug release is often first order from such matrixes. 
 
Hence the following must be considered: 
• The chemical nature of support (generally, the support are formed by polymers         
• The physical state of drug (dispersed under molecular or particulate form or both) 
• The matrix shape and alteration in volume as a function of time. 
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• The route of administration (oral administration remains the most widely used but               
other routes are adaptable .  
 
Derivation of the mathematical model to describe this system involves the following 
assumptions: 
• A pseudo steady state is maintained during drug release.  
• The diameter of the drug particles is less than the average distance of drug 
diffusion    through the matrix.  
• The bathing solution provides sink conditions at all times.  
• The diffusion coefficient of drug in the matrix remains constant i.e. no change in 
the   characteristics of the polymer matrix. 
 
Types of Matrix Tablets 
There are 3 Types of Matrix Tablets 
a. Hydrophilic matrixes 
b. Fat wax matrixes 
c. Plastic matrixes 
 
a. Hydrophilic Matrixes18  
Several commercial patented hydrophilic matrix systems are currently in use, 
such as synchronal technology and hydro dynamically balanced system.  
e.g. Sodium Carboxy Methylcellulose, Methyl Cellulose, Hydroxy propyl Methyl 
Cellulose, Hydroxyl Ethyl cellulose, Polyethylene Oxide, Poly Vinyl Pyrrolidine, Poly 
Vinyl Acetate, Gelatin, Natural Gums etc. 
 
Mechanism of drug release from matrix devices19  
Sustained release oral products employing dissolution as the time limiting step 
are simplest to prepare. If a drug has a rapid rate of dissolution it is possible to 
incorporate it into a table t with a carrier that has a slow rate of dissolution.  
In the dissolution process if the dissolution process is diffusion layer control, the 
rate of diffusion of drug from the solid surface to the bulk solution through an unstirred 
liquid film, is the rate limiting step. In this case the dissolution process at steady state 
would be described by Noyes-Whitney equation 
  dc/dt = KDA (Cs-C) ------------------ (1) 
Where, 
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dc/dt is dissolution rate.  
KD dissolution rate constant. 
Cs is saturation solubility of drug. 
C is the concentration of drug in bulk of the solution. 
In relation to diffusion expression, that 
KD = D/v*I ----------------------- (2) 
Where, D is dissolution coefficient 
 V volume of dissolution media 
 I is the thickness of unstirred liquid film. 
 
From the above expression it can be seen that the rate of dissolution i.e. 
availability is approx. proportional to the solubility of the drug in the dissolution media 
i.e. (Cs) provided a constant area and diffusion path length are maintained. This equation 
predicts constant dissolution rate as long as enough drug is present to maintain Cs 
constant, provided surface area does not change. 
 
Advantages of hydrophilic matrix tablets: 
• With proper control of the manufacturing process, reproducible release profiles    
are possible. 
• The variability associated with them is slightly less than that Characterizing.   
Coated release form. 
• Structure allows an immediate release of small amount of active principle there is              
no risk of dose dumping. 
• Their capacity to incorporate active principle is large, which suits them to 
delivery   of large doses.  
• The manufacturing processes are notably simple. Table t formulation can be done   
via direct compression or by wet granulation techniques 
• Large variety of non expensives gelling agents is approved for oral use by the    
competent official organization. 
• The safety margin of high-potency drugs can be increased. 
• The drug release from hydrophilic matrices show a typical time dependent profile 
i.e. decreased drug release with time because of increased diffusion path length.  
 
  
Introduction
Dept.	of	Pharmaceutics,	KMCH	College	of	Pharmacy	 	21	
 
Disadvantages of hydrophilic matrix tablets: 
• Not suitable  for water insoluble materials. 
• Drug layering or drug coating is impossible. 
 
b. Fat wax matrixes 
The drug can be incorporated into fat wax granulations by spray congealing in 
air, blend congealing in an aqueous media with or without the aid of surfactants and 
spray drying techniques. Mechanism 
• Delivery by diffusion. 
• Delivery by surface erosion. 
 
c. Plastic matrixes.  
With plastic material(s) tablets can be easily prepared by direct compression of 
drug provided the plastic material can be comminuted (or) granulated to desired particle 
size to facilitate mixing with drug particles. e.g, Polyvinyl chloride, Polyethylene, 
Vinyl Acetate, Vinyl Chloride Copolymer, Acrylate or Methyl Methacrylate Copolymer, 
Ethyl Cellulose, Cellulose Acetate, Polystyrene. 
 
1.4.3. Methods may be used to disperse drug and additives in the retardant base19 
• A solvent evaporation technique can be used in which a solution /dispersion of   
drug and additive is incorporated into the molten wax phase. The solvent is    
removed by   evaporation. 
• Dry blends of ingredients may be slugged and granulated. more uniform    
dispersion,   however, can be  prepared by the fusion technique, in which drug 
and additive are blended into the molten wax matrix at temperatures slightly 
above the  melting   point.(e.g., approximately 90°c for carnauba wax.) 
• The molten material may be spray congealed, solidified and milled, solidified   
and flaked or poured on cold rotating drum to form sheets, which are then milled       
and screened to form a granulation.  
• The process used to prepare formulation for compression depends on the polymer   
and drug: polymer ratio. 
• With high drug: polymer ratios, a wet granulation process is required. Low   
Milligram    potency formulations may be directly compressed /granulated using   
alcohol if the  polymer is not in a form amenable to direct compression.  
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1.4.4 .     Materials used as retardants in matrix table t formulations  
Table . 2 
Matrix type Retardants 
Water insoluble inert 
materials 
Polyethylene, Polyvinyl Chloride, Methyl Acrylate, 
Methacrylate Co-Polymer, Ethyl Cellulose. 
Water insoluble 
erodible materials 
Carnauba was, Stearyl Alcohol, Stearic acid, PEG, 
Hydrogenated Castor Oil, PEG Monostearate, Triglycerides. 
Hydrophilic materials Hydroxy Ethyl Cellulose, HPMC, Sodium CMC, 
Methylcellulose, hydroxy ethyl cellulose.  
Natural polymers Galactomannose (guar gum), chitosan, gum acacia, bean gum, 
sodium alginate, karaya gum, pectins, Xanthan gum. 
 
1.4.5. Factors influencing the drug release from matrix 
• Choice of matrix material. 
• Amount of drug incorporated in the matrix. 
• Viscosity of the hydrophilic material in aqueous system at a fixed 
concentration.  
• Drug: matrix ratio and particle size of the drug. 
• Table t hardness, porosity and density variation. 
• Entrapped air in tablets. 
• Table t shape and size. 
• Solubility of drug in aqueous phase. 
• Surfactants and other additives 
 
B. Reservoir Dissolution Control Systems 
This system containing an inner core of drug surrounded in a water insoluble 
polymer membrane. The polymer can be applied by coating or microencapsulation 
methods. The drug release mechanism across the membrane involves its partitioning into 
the membrane with subsequent release into surrounding fluid by diffusion. The polymers 
commonly used in such devices are Hydroxypropyl cellulose, Ethylcellulose and 
polyvinyl acetate. Disadvantage of the method is chance to sudden dose dumping which 
is not common with matrix tablets.  
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A plot of fraction of drug released against time will be linear if the release obeys 
zero order release kinetics.     
 
B. First order release kinetics 
 Wagner assuming that the exposed surface area of the table t decreased 
exponentially with time during dissolution process suggested that drug release from most 
slow release tablets could be described adequately by apparent first-order kinetics. The 
equation used to describe first order kinetics is  
 ln (1-Q) = - K1 t 
Where 
Q = Fraction of drug released at time‘t’ 
K1 = First order release rate constant 
Thus, a plot of logarithm of the fraction of drug remained against time will be 
linear if the  release obeys first order kinetics. 
 
c. Higuchi equation 
It defines a linear dependence of the active fraction released per unit of surface 
(Q) on the square root of time. 
 Q = K2 t1/2  
Where 
Q = Fraction of drug released at time‘t’ 
K2 = release rate constant  
A plot of fraction of drug released against square root of time will be linear if the 
release obeys Higuchi equation. This equation describes drug release as a diffusion 
process based on   Fick’s law, square root of time dependent.  
 
1.4.8. Principle of modified drug release 
Following either of the two principles can modify drug release 
 
a. Barrier principle 
 In this method the retardant material is imposed between the drug and elusion 
medium. Drug release is by diffusion of the drug through the barrier and /or erosion of 
the barrier or permeation of the barrier by moisture.  
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Fig: 6 Drug diffusion through the barrier, B.permeation of barrier by elution media 
followed by drug dissolution. C, Erosion of barrier releasing drug, D ruptures of 
permeation of elution media. [Manion C.V (1977) Welling.G (1978)] 
 
b. Embedded matrix 
In this drug is dispersed embedded in a matrix of retardant material that may be 
encapsulated in a particulate form or compressed into the table t. Drug release occurs by 
permeation of water leaching extraction of diffusion of drug from the matrix and erosion 
of the matrix and erosion of matrix material.   
 
Fig: 7 Embedded matrix concept as a mechanism of controlled released in sustained 
release dosage form design network model a drug is insoluble in the retardant material. 
B Drug is soluble in the retardant material. [Wu .JC (1993), Alfrey .TJR (1966) ] 
 
1.4.9. Recent trends in sustained drug delivery system  
 Sustained release dosage forms are categorized as      
  A. Single unit dosage form. 
  B. Multiple unit dosage form.  
  C. Mucoadhesive system. 
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A. Single unit dosage form:  
 These refer to diffusion system where the drug is uniformly distributed (dispersed 
dissolved) throughout the solid matrix and the release of the drug is controlled or 
sustained either by incorporating hydrophilic or hydrophobic filler within the matrix or 
by coating the drug matrix with a swellable or non-swellable polymer film. These 
systems can be classified as: 
 
a. Monolithic system: 
 If the release rate is controlled or sustained by incorporating hydrophilic or 
hydrophobic filler within the matrix then the system is called as Monolithic device where 
the diffusion of drug through the matrix is rate- limiting step.  
 
b. Hydrophobic/Swellable table t: 
 Table t prepared by mixing the drug with hydrophobic/hydrophilic filler appear to 
extend the release time of the drug from device within the GI tract after oral 
administration. 
 
c. Floating table t or capsule: 
 Designing of Floating table t or capsule are called hydro-dynamically balanced 
drug delivery system is based on the principle that device with gravity lesser than that of 
the gastric juice of stomach and retain the drug in the proximal region of the GIT. 
 
d. Semisolid matrix system: 
 In this system, the hydrophobic carrier occurs in an oily semisolid state where the 
drug is incorporated and the final mass is usually filled into gelatin capsule to prepare the 
dosage form. 
 
e. Coated table t and Similar Multilayer system: 
Multilayer systems are designed in such a way that the drug has to cross a barrier 
or membrane on its way from the device to the physiological environment. The nature 
and the number of barriers control the release process. 
 
In the simplest form coated table t comprised a core containing the drug and a 
coating layer, which surrounds the core. The core is usually the drug either alone or 
loaded on to an inert material (hydrophilic or hydrophobic). 
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Multilayered table t having two or more distinct layers usually prepared by dry 
coating technique have also been used to formulate sustained or controlled preparations 
for water-soluble drugs. In this case, coating which controls the release process covers 
the core table t containing the drug only partially. 
 
f. Osmotic device: 
In osmotic device usually an osmotic agent (often with an osmotic adjuvant) is 
contained within a rigid compartment that is separated from the osmotic compartment by 
a partition. In the physiological environment the aqueous fluid penetrates across the 
membrane and the increased volume within the osmotic compartment pushes the drug 
out of the device through a delivery orifice.  
 
B. Multiple unit dosage forms:  
It represents a combination of subnets of the dosage forms, the source of which 
may either be homogeneous or heterogeneous. It offers the advantages of releasing one 
of the drugs or part of the same drug immediately  
 
While remaining drug or parts of the same can be sustained release. These are 
useful where drug-Excipients and drug-drug interactions are inevitable  in a single unit 
dosage form.e.g. are Micro ranules / Sphéroïdes, Beads. Pellets. Micro capsules.                         
 
C. Mucoadhesive systems:  
It utilizes principle of bioadhesion for optimum delivery of the drug from the 
device. Bioadhesion is definable as the occurrence in which one biological substance is 
adhered to another substance, which may either, be of biological or non-biological 
origin. If the substance is mucosal membrane the phenomenon is known as 
mucoadhesion. 
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2. AIM AND OBJECTIVE 
Need for the study  
Over the last three decades sustained release technology has received increasing 
attention from the pharmaceutical industry due to its increased clinical value as well as 
extended product life. Treatment of a disease or infection in most cases requires 
maintaining a desired drug plasma concentration level over a prolonged period of time. 
Such clinical needs often are satisfied by a multiple dose therapy, which can involve 
frequent dosing of two to four doses per day. It can be very difficult for patients to stick 
to such stringent routines, which can lead to poor patient compliance and, consequently, 
the desired drug plasma concentration level can be below the acceptable minimum 
therapeutic concentration. This can lead to inadequate relief and/or the development of a 
tolerance to the drug.  
 
The most common approach to minimizing patient noncompliance is by using 
extended release drug delivery system to decrease the number of doses that must be 
taken each day. One useful approach in this regard involves using a polymer based 
matrix in which the drug is uniformly dispersed or dissolved.  Approach for higher doses 
(based on weight) and prolonged release formulations are challenging task in formulation 
development. Hence, there is still a need in the art for modified release dosage based 
formulation. 
 
Objectives  
¾ The main aim of the present work is to formulate and evaluate sustained 
release matrix tablets of metformin (750mg) using 5 different polymers of 4 
different concentration (20,25, 30 & 35%).  
 
¾ To estimate the physio-chemical properties and invitro drug release profile of 
the formation with the innovator (Glucophage XR) 
 
¾ To choose the best drug formulation from the above evaluations.  
 
¾ To subject the most satisfactory formulation based on the above studies for 
accelerated studies.  
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3. LITERATURE REVIEW 
 
1. Shukka Taphan, et al.,22 carried out a research work to develop an extended 
release metformin Hcl tablet and to study effect of additives on the drug release 
mechanism . The polymer used is the HPMC K 100 M .The polymer ratio is 3.3 
:1 gives 91 % drug release over 11 hour study in non linear fraction . Water up 
takes study showed that HPMC had a slow hydration and swelling rate in non 
linear fashion during the first hour. After 1 hour showed a linear up take profile. 
Metformin with soluble or in soluble additives with HPMC showed lower 
swelling compared to tht of metformin hcl with hpmc tablet (reference) in soluble 
additives are mcc, dcp, starch . Soluble additives are Nacl, lactose, an hydrous 
pregelatinized starch, sls, providone. 
 
2. Dinda, et al.,23  carried out a research work to design a formulation to improve 
the oral therapeutic efficiency with optimal control of plasma drug level which 
contains two anti diabetic drug metformin and glimepridine . metformin sustained 
release and glimepride an immediate release as a bi layer tablet . Two 
formulations with hydrophilic swellable polymer and other with hydrophobic 
polymer for sustained delivery from matrices. hydroxyproplymethylcellulose and 
polyethylene oxide used as polymer for sustained release.  
 
3. Milind Janrao Umekar, et al.,24 studied to develop the oral sustained release 
metformin hydrochloride tablet formulations using lipophilic waxes such as 
hydrogenated caster oil , stearic acid and glyceryl mono sterate either alone or 
their combinations by melt granulation . The drug release kinetics demonstrated 
that hydrogenated caster oil sustained the release of metformin grater than the 
stearic acid and glyceryl mono sterate. 
 
4. Jaime Davidson and Harry Howlett25 studied the new prolonged release 
metformin improves gastro intestinal tolerability . metformin mainly 
administrated to patients with type 2 diabetes  , but side effect may be high such 
as gastrointestinal side effects and complex administration regimen . New 
prolonged release metformin formulation (GLUCOPHAGE SR ) , given once 
daily in placebo controlled trials . It lowers the side effect . The improved 
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tolerability associated with prolonged release metformin probably arises from the 
tablet design , which releases metformin in to the upper intestine by diffusion 
from a dual hydrophilic polymer matrix (Gel shield diffusion system) . This 
provides slower , smoother and longer drug delivery , with out an initial rapid rise 
in plasma metformin. 
 
5. Milind J, et al.,26 studied the formulation and evaluation of sustained release 
matrix tablet of metformin hydrochloride using ph dependent and ph independent 
methacrylate polymers , by direct compression of drug and different ph 
dependent Eudraget L100 and S 100 and ph indipentent Eudraget RLPO and 
RSPO polymer combinations . evaluation provided that S IOO RLPO and S100 / 
RSPO mixture give maximum sustained action . 
 
6. Sundaramoorthy. K, et al.,27 studied the in vitro and in vivo release of metformin 
SR tablets , ethyl cellulose as the polymer. Concentrations of drug vary and 
polymer constant. The drug polymer ratio 5:3 more successful of study. 
 
7. Natalie Foster and Kyle A Fliszar28 studied a continuous dissolution/absorption 
system using a hexadecane membrane ( HDM) as the permeation measurement 
has been examined for 3 distant formulations of Metformin HCL . this system 
was used to correlate the absorption rate of metformin through the membrane 
after release from the dosage form to rate of the appearance of metformin in the 
plasma from the same formulation. 
 
8. David Stepensky and Michael Friedman29  studied the pharmacokinetic (PK) and 
pharmacodynamic (PD) rationales to develop controlled release(CR)formulations 
of metformin. Unrestrained diabetic rats received the drug as intravenous bolus 
(i.v.), oral solution (p.o.),intra-duodenal bolus, 4-h infusion, or intra-colonic 
bolus. In addition, we developed two CR-gastroretentive dosage forms(CR-
GRDF) that released the drug over 3 or 6 h (in vitro), and retained in the rats’ 
stomach for 8–10 h. Metformin exhibitedflip-flop PK. The colonic absorption 
was low but sustained and was associated with highly variable glucose-lowering 
effects,thus providing a PK rationale to develop CR-GRDF. In addition, the 
glucose-lowering effect was greater following p.o. vs.i.v. administration, despite 
equivalent AUC, indicating a first pass PD effect, thus, adding a PD rationale to 
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developmetformin CR-GRDF. When administered to the diabetic rats, CR-
GRDFs produced bioavailability and extent of glucoseloweringeffects that were 
similar to those of the duodenal infusion and p.o. metformin administration. 
These findings areattributed to the adsorption of metformin to the intestine that 
yields slow and prolonged absorption even following p.o.administration of drug 
solution. The data indicates that unless the CR formulation could significantly 
extend the absorptionperiod, it is not likely to improve glucose-lowering efficacy 
 
9. Saptarshi Dutta, et al.,30  formulate the oral sustained release Metformin 
hydrochloride matrix tablets by using hydroxyl methyl cellulose polymer 
(HPMC) as rate controlling factor and to evaluate drug release parameters as per 
various release kinetic models. It is observed that the basic goal of therapy in the 
development of Metformin hydrochloride release dosage form is to increase 
bioavailability; reduce risk of hospitalization, deliver drug at a near constant rate 
for approximately 12 hrs, independent of food intact and gastrointestinal PH. The 
dry granulation technique was used to compress the tablet as powder showed the 
poor flowability; less cohesiveness during direct compression and due to 
moisture sensitivity and tendency to hydrolyte, wet granulation techniques was 
not selected for the present work. Dry granulation improves the flow of the 
powder and reduces the use excipients. The granules were evaluated for angle of 
repose, loose bulk density, tapped bulk density, compressibility index, total 
porosity, drug content etc. and showed satisfactory results. The tablets were 
subjected to thickness, weight variation test, drug content, hardness, friability and 
in vitro release studies. The in vitro dissolution study was carried out for 12 hours 
using PH 4.0, 6.8 Phosphate buffer & pH 1.2 buffer in phosphate buffer as 
dissolution media. All the tablet formulations showed acceptable 
pharmacotechnical properties and complied with pharmacopoeial specifications. 
The mechanism of drug release form matrix tablet is govorenered by diffusion 
and as the drug is so highly soluble. However, when considering in-vivo behavior 
of this system, the erosion rate will be more important. 
 
10. Paola Mura, et al.,31 had investigated because of   low bioavailability and short 
half-life of metformin hydrochloride (MH) make the development of sustained-
release forms desirable. However, drug absorption is limited to the upper 
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gastrointestinal (GI) tract, thus requiring suitable delivery systems providing 
complete release during stomach-to-jejunum transit. This study was undertaken 
to develop a MH sustained-release formulation in compliance with these 
requirements. The strategy proposed is based on direct-compressed matrix tablets 
consisting of a combination of MH with the hydrophobic triacetyl-β-cyclodextrin 
(TAβCD), dispersed in a polymeric material. Different polymers were tested as 
excipients, i.e. hydroxypropylmethylcellulose, xanthan gum, chitosan, 
ethylcellulose, Eudragit®L100-55, and Precirol®. Compatibility among the 
formulation components was assessed by DSC analysis. All the tablets were 
examined for drug release pattern in simulated gastric and jejunal fluids used in 
sequence to mimic the GI transit. Release studies demonstrated that blends of a 
hydrophobic swelling polymer (hydroxypropylmethylcellulose or chitosan) with 
a pH-dependent one (Eudragit®L100-55) were more useful than single polymers 
in controlling drug release. Moreover, the main role played by the MH-TAβCD 
system preparation method (i.e. grinding or spray-drying) in determining the 
behaviour of the final formulation was evidenced. In fact, for a given matrix-
tablet composition, different sustained-release effects were obtained by varying 
the relative amounts of MH-TAβCD as ground or spray-dried product. In 
particular, the 1:1 (w/w) blend of such systems, dispersed in a Eudragit–chitosan 
polymeric matrix, fully achieved the prefixed goal, giving about 30% released 
drug after 2 h at gastric pH, and overcoming 90% released drug within the 
subsequent 3 h in jejunal fluid. 
 
11. Lian – Dong Hu, et al.,32 In this study, metformin hydrochloride (MH) sustained-
release pellets were successfully prepared by centrifugal granulation. Seed cores 
preparation, drug layering, talc modification and coating of polymeric 
suspensions were carried out in a centrifugal granulator. Talc modification was 
performed before coating in order to overcome the high water solubility of 
metformin. The influence of surface modification by talc, the effects of Eudragit® 
types and ratios, as well as the correlation between in vitro release and in vivo 
absorption were investigated in detail. Experimental results indicated that talc 
modification made a decisive contribution to controlling the drug release by 
avoiding drug dumping. Three dissolution media: 0.1 M HCl, distilled water and 
pH 6.8 phosphate buffer were employed to determine the in vitro release 
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behaviors of the above metformin hydrochloride pellets. The relative 
bioavailability of the sustained-release pellets was studied in 12 healthy 
volunteers after oral administration in a fast state using a commercially available 
immediate release tablet (Glucophage) as a reference. Following coating with a 
blend of Eudragit® L30D-55 and Eudragit® NE30D (1:20), at 7% or 10% coating 
level, respectively (referred to as F-2, F-3), the pellets acquired perfect sustained-
release properties and good relative bioavailability. The Cmax, Tmax and relative 
bioavailability for F-2 and F-3 coated pellets were 1.21 µg/ml, 6 h, 97.6% and 
1.65 µg/ml, 8 h, 165%, respectively. Combined use of two Eudragit® polymers 
with different features as coating materials produced the desired results. 
Restricted delivery of metformin hydrochloride to the small intestine from 
differently coated pellets resulted in increased relative bioavailability and a 
sustained release effect. The adoption of several different pH dissolution media 
established a better relationship between the in vitro release and in vivo 
absorption of the sustained-release pellets. 
 
12. Kulang – Hee Shin, et al.,33 studied the combination of glimepiride and 
metformin is used for glycemic control in patients with diabetes mellitus. A 
fixed-dose combination of glimepiride/metformin 2/500 mg slow-release (SR) 
formulation was developed to improve compliance in polymedicated patients. To 
accommodate the various dosing regimens of glimepiride, a glimepiride / 
metformin 1/500 mg SR tablet was also developed 
 
13. Sfalchi, et al.,34 had studied the   Oral absorption of the antihyperglycaemic agent 
metformin (MF·HCl) is confined to the upper part of the intestine, therefore 
controlled-release oral formulations of this drug should ensure a complete release 
during transit from stomach to jejunum. Compressed matrix tablets based on pH-
sensitive poly(ethylene oxide) (PEO)–Eudragit L100 (EUD L) compounds have 
shown in vitro a compliance with the above requirement. The polymer 
compounds were prepared by a coevaporation process. The release pattern of 
MF·HCl from matrices depended on the PEO–EUD L ratio in the coevaporate. 
The 1:1 (w/w) ratio was unable to control MF·HCl release in simulated gastric 
fluid (SGF, pH 1.2), because the matrix material was excessively hydrophilic. 
Nevertheless, the release rate in SGF could be modulated by increasing the EUD 
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L fraction in the coevaporate. With a PEO (Mw, 400 kDa)–EUD L (1:2, w/w) 
ratio the percent dose released in 2 h to SGF, where the coevaporate was 
insoluble, was around 23 or 50% with 10 or 20% loading dose. The release was 
then completed within the successive 2 h of elution with simulated jejunal fluid 
(SJF, pH 6.8) where EUD L and the coevaporate gradually dissolved. Release in 
SGF was controlled by matrix swelling and/or drug diffusion in matrix, whereas 
matrix dissolution controlled release in SJF. The unique release-controlling 
properties of the polymer compounds were due to PEO–EUD L macromolecular 
interactions. Matrices show promise of a gradual and complete release of 
MF·HCl from stomach to jejunum, unaffected by gastric pH fluctuations. This 
mode of administration might allow the use of lower therapeutic doses compared 
to existing immediate- or sustained-release products, thus minimising side 
effects. 
   
14. Anil K Babbar, et al.,35 the objective of the present study was to develop a 
hydrodynamically balanced system of metformin as a single unit floating capsule. 
Various grades of low-density polymers were used for the formulation of this 
system. They were prepared by physical blending of metformin and the polymers 
in varying ratios. The formulation was optimized on the basis of in vitro 
buoyancy and in vitro release in simulated fed state gastric fluid (citrate 
phosphate buffer pH 3.0). Effect of various release modifiers was studied to 
ensure the delivery of drug from the HBS capsules over a prolonged period. 
Capsules prepared with HPMC K4M and ethyl cellulose gave the best in vitro 
percentage release and were taken as the optimized formulation. By fitting the 
data into zero order, first order and Higuchi model it was concluded that the 
release followed zero order release, as the correlation coefficient (R2 value) was 
higher for zero order release. It was concluded from R2 values for Higuchi model 
that drug release followed fickian diffusion mechanism. In vivo studies were 
carried out in rabbits to assess the buoyancy, as well as the pharmacokinetic 
parameters of the formulation using gamma scintigraphy. The formulation 
remained buoyant during 5 h of study in rabbits. The comparative 
pharmacokinetic study was performed by administration of the optimized HBS 
capsules and immediate release capsules, both with radiolabeled metformin, 
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using gamma counter. There was an increase in AUC in optimized HBS capsules 
of metformin when compared with immediate release formulation. 
 
15. Kamlesh J Wadher, et al.,36 studied metformin hydrochloride has relatively short 
plasma half life, low absolute bioavailability. The need for the administration two 
to three times a day when larger doses are required can decrease patient 
compliance. Sustained release formulations that would maintain plasma level for 
8 -12 h might be sufficient for daily dosing of meformin. The overall objective of 
the present work was to develop an oral sustained release metformin tablet 
prepared by direct compression method, using hydrophilic Eudragit RSPO and 
RLPO alone or in combination with hydrophobic ethyl cellulose polymer as rate 
controlling factor. All the batches were evaluated for thickness, weight variation, 
hardness, and drug content uniformity and in vitro drug release. Mean dissolution 
time is used to characterize drug release rate from a dosage form and indicates 
the drug release retarding efficiency of polymer. When Endragit RSPO and 
RLPO were used alone as the only retarding polymer, a sustained drug release 
pattern were not observed while, Inclusion of ethylcellulose in the matrix almost 
doubled (12 h) the time required for releasing the drug. Kinetic modeling of in 
vitro dissolution profiles revealed the drug release mechanism ranges from 
diffusion controlled to anomalous type. Fitting the data of Korsmeyer equation 
indicated that diffusion along with erosion could be the mechanism of drug 
release.  
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5. DRUG PROFILE  
Drug Class 
Anti diabetic drug                
    
METFORIMIN HYDROCHLORIDE37 
Chemical Name  -  N,N-dimethylimidodicarbonimidic diamide hydrochloride  
Empirical Formula  - C4H11N5  
Molecular Weight - 165.63  
Structural Formula  - 
 
 
Category   - Oral Anti hyperglycaemic  
Appearance  - While Crystal 
Solubility   - Freely Soluble in Water, Slightly Soluble In Alcohol  
,Insoluble In Acetone And Dichloromethane 
ADR    - Distributed to mother milk and had effect on infants  
Pharmaco Kinetics - Slowly Absorbed by GI tract, 500mg DrugÆ 50-60%  
Absorbed again reduced when taken with food 
 
HALF LIFEÆ2 TO 6 HOURS37  
 Mechanism 
¾ Decrease the glucose tolerance 
¾ Decrease hepatic glucose production 
¾ Decrease intestinal absorption of glucose 
¾ Improves insulin sensitivity by increasing peripheral glucose uptake and 
utilization  
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BRANDS       
 Glucophage  
 Fortamet 
 Riomet 
 
Pharmacokinetics & Pharmacodynamics 
Absorption 
It is rapidly absorbed after oral administration with peak plasma or serum 
concentrations appearing within1.5-2 hours .oral   absorption is estimated to be 80% of 
the dose. 
 
Metabolism37 
The drug rapidly metabolized through oxidation and glucuronic acid conjucation 
with urinary excretion of inactive metabolites usually complete within 24 hours.  
 
Mechanism of action37 
 Metformin is an anti hyperglycemic agent which improves glucose tolerance in 
patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its 
pharmacologic mechanisms of action are different from other classes of oral anti 
hyperglycemic agents. Metformin decreases hepatic glucose production, decreases 
intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral 
glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce 
hypoglycemia in either patients with type 2 diabetes or normal subjects and does not 
cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged 
while fasting insulin levels and day-long plasma insulin response may actually decrease. 
 
Excretion 
Less than10% of administered NSAIDS is eliminated in urine. 
 
Plasma half life   
6.2 hours. 
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6. EXCIPIENTS PROFILE 
 
6.1. Hydroxy Propyl Methyl Cellulose38 
Structure 
 
Molecular Formula : C56H108 O30 
Molecular Weight : 3912.39 
Description  : White of white powder 
 
Solubility 
 Swells in cold water , in soluble in hot water , soluble in most organic solvents. 
 
Melting Point 
 56.2°C 
 
Density  
 1.39g/cm3 
 
Chemical Properties 
 Hpmc is cellulose either, derived from alkali treated cellulose that is reacted with 
methyl chloride and propylene. 
 
USE 
 HPMC is an enteric film coating material or a matrix binder in solid dosage 
forms. It is used as a viscosity control agent, gelling agent, film former, stabilizer, 
dispersant, lubricant, binder, emulsifying agent and suspending agent end applications 
include adhesieve, building materials , personal care products, detergents and surfactants, 
printing and coatings , pharmaceutical food products , polymerization and textiles.       
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process. In addition to it is used as binder, diluents. Micro crystalline cellulose also had 
some lubrication and disintegrates properties that make it useful in tabletting.MCC is 
also used in cosmetics and food products. 
Description  
 Microcrystalline cellulose is purified partially depolymerized cellulose that occur 
as a white, odorless, tasteless, crystalline powder composed of porous particles. It is 
commercially available in different particle size and moisture grades that have different 
properties and applications. 
Typical Properties 
Angle of repose - 49 degree for ceolus KG 
    34.4 degree for emcocel 90 M 
Flow Ability  - 1.41 gls for emocel 90 M 
Melting Point  - Chars at 260-270 degree Celsius  
Moisture Content - Typically less than 5% w/w however different grades may  
    contain varying amount of water.MCC is hydroscopic. 
 
Particle Size Distribution 
 Typical mean particle size is 20 to 200 micrometer 
 
Solubility 
 Slightly soluble in 5  % w/v of Sodium hydroxide solution practically insoluble in 
water , dilute acids and most organic solvents . 
 
Use Of MCC 
USE CON % 
Adsorbent 
Anti adherent  
Capsule binder/diluents 
Tablet disintegrant 
Tablet binder / diluents 
20  - 90% 
 5 – 20% 
 20 – 90% 
  5  -   15% 
 20   -90% 
 
Stability And Storage Conditions 
 MCC is stable through hydroscopic material. The bulk material should be stored 
in a well closed container in a cool, dry place. 
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6.3. ETHO CEL40 
Structure  
 
Synonym  - Cellulose Ethyl Ether e462 ,Surlease , Ethyl Cellulose 
Preparation 
 Prepared from wood pulp or by chemical treatment with alkali and ethylation of 
the alkali cellulose with ethyl chloride. 
 
Functional Category 
 Counting agent, tablet binder viscosity-increasing agent . 
 
Description 
 Ethyl cellulose is tasteless, free flowing 
 
Typical Properties 
 Practically insoluble in glycerin, propylene glycol and water. Ethyl cellulose 
contains less than 46.5% of ethoxy  group is freely soluble in CHCL3 . Methyl acetate, 
tetra hydrocarbons with ethanol 95% . ethyl cellulose that is freely soluble in chloroform, 
ethanol 95% ethyl acetate , methanol and toluene . 
 
Viscosity 
 Various grades of ethyl cellulose are commercially available which differ in their 
ethoxy content and degree of polymerization. The viscosity of solutions increases with 
an increase un concentration of ethyl cellulose. 
 
Stability and Storage Conditions 
 Ethyl cellulose is a stable, slightly hydroscopic material . it is chemically resistant 
to alkali , both dissolve and concentrated and to salt solution, although it is more 
sensitive to acidic materials than cellulose ester. Ethyl cellulose is subjected to oxidation 
in the presence of sunlight or uv light at elevated temperature .this may absorption 
properties between 230 to 340 nm .the bulk materials should be stored in a dry place in a 
well closed container. 
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Safety  
 Ethyl cellulose is a stable, slightly hydroscopic material. It is chemically resistant 
to alkali. Although it is more sensitive to acidic materials than cellulose esters .Ethyl 
cellulose is subjected to oxidative degradation in the prescience of sunlight or UV light 
at elevated temperature. This may be prevented by the use of an antioxidant and a 
compound with light absorption properties between 230-340 nm. The bulk materials 
should be stored in a dry place, in a well closed container. 
 
Use 
 Ethyl cellulose is widely used in oral and topical pharmaceutical formulation. It is 
used in food products. Ethyl cellulose is not modified following oral conception and is 
there for a non caloric substance. In general it is regarded as a non toxic non allergenic 
and non irritant material. Since ethyl cellulose is not metabolized it is recommended for 
using parental products. 
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Application in Pharmaceutical Formulation And Technology 
 Magnesium sterate is widely used in cosmetics, food and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture of 
concentrations between 0.25% and 5.0 w/w 
 
Description 
 Magnesium sterate is very fine , light weight ,precipitated or milled , implantable 
powder of low bulk density , having a faint odor of stearic acid and a characteristic taste . 
The powder is greasy to touch and readily adheres to skin. 
 
Melting Point 
 117 – 150°c (commercial samples) 
 126 – 130°c(highly purity magnesium sterate) 
 
Solubility 
 Practically in soluble in ethanol , ethanol(95%) either and water . slightly soluble 
in warm benzene and warm ethanol (95%) 
 
Stability and Storage Conditions 
 Magnesium sterate is stable and should be stored in a well closed container in a 
cool  , dry place .  
 
6.5. POLYOX WSR 30042 
Non Proprietary Name 
USPNF ; Polyethylene Oxide 
Synonyms 
Polyox , Polyoxirane , polyoxyethylene 
Description 
• White off white 
• Free flowing 
• Slightly ammonical odour 
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Chemical name 
Polyethylene oxide 
Molecular weight 
7000000 
Strectural formula 
(CH2CH2O)n      n is the no of oxyethylene gou 
Application 
Mucoadhersive polymer , Tablet binder(5 – 85%) , Thicknening agent , In higher 
molecular weight it is used as a sustained release polymer via the hydrophilic matrix 
approach 
Deferent grades 
¾ WSR N - 10 
¾ WSR N -80 
¾ WSR N -750 
¾ WSR N - 3000 
¾ WSR N -1105 
¾ WSR N - 12K 
¾ WSR N – 60K 
¾ WSR N – 301 
¾ WSR  coagulant 
¾ WSR  300 
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4. METHODOLOGY 
4.1. Materials and Methods 
List of Excipients and their Functions  
Table: 3 
Sl no Ingredients Function 
1 Methocel K100M Polymer  
2 Methocel K15M Polymer 
3 Methocel K4M Polymer 
4 Ethocel  20 prem Polymer 
5 Polyox WSR 300 Polymer 
6 MCC Ph 101 Diluents  
 
List of equipments used  
Table : 4 
Equipment Manufacturing company 
Electro balance Mettle Toledo , USA 
Bulk density apparatus Electrolab , mumbai 
Rapid mixer granulator Anchor , mumbai 
Double cone blender Erweka 
Rotary tablet punching machine Rimek , mumbai 
Friability test apparatus Electro lab , Mumbai 
Tablet hardness tester Schleniger hardness tester 
Fludised bed drier Anchor mumbai 
Disintegration test apparatus Electro ,mumbai 
Sonic swifter Erweka 
Tablet dissolution apparatus Electrolab , mumbai 
Helium lamp (LOD) Mettler , taledo 
Thickness (vernier calipers) Mitutogo vernier calipers 
Stability chambers Thermo lab 
Hot air oven Eltek motors mumbai 
Hplc Ezchrom Elite 
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4.2 INNOVATOR DETAILS                         
GLUCOPHAGE - metformin hydrochloride tablet, film coated 
GLUCOPHAGE XR - metformin hydrochloride tablet, extended release 
Bristol-Myers Squibb Company 
Active Incredent         : Metformin Hydrochloride  
Dosage Form (oral)  : Tablet , Extended Release  
Proprieky Name     : Glucophase  XR 
Applicant          : Bristal Myers Squibb  
Strength       : 500 mg 
Applicant No      : 21202  
Product No       : 001 
Approval Date       : Oct 13 , 2000 
Ref listed Drug       : Nil  
 
Description 
GLUCOPHAGE® (metformin hydrochloride) Tablets and GLUCOPHAGE® 
XR (metformin hydrochloride) Extended- Release Tablets are oral antihyperglycemic 
drugs used in the management of type 2 diabetes. Metformin hydrochloride (N, N 
dimethylimido dicarbonimidic diamide  hydrochloride) is not chemically or 
pharmacologically related to any other classes of oral  anti hypo glycemic drug. 
 
GLUCOPHAGE tablets contain 500 mg, 850 mg, or 1000 mg of metformin 
hydrochloride. Each tablet contains the inactive ingredients providone and magnesium 
stearate. In addition, the coating for the 500 mg and 850 mg tablets contains 
hypromellose andthe coating for the 1000 mg tablet contains hypromellose and 
polyethylene glycol. 
 
GLUCOPHAGE XR contains 500 mg or 750 mg of metformin hydrochloride as 
the active ingredient. 
 
GLUCOPHAGE XR 500 mg tablets contain the inactive ingredients sodium 
carboxymethyl cellulose,hypromellose, microcrystallinecellulose, and magnesium 
stearate. 
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GLUCOPHAGE XR 750 mg tablets contain the inactive ingredients sodium 
carboxymethyl cellulose, hypromellose, and magnesium stearate. 
 
System Components and Performance–GLUCOPHAGE XR comprises a dual 
hydrophilic polymer matrix system. Metforminn hydrochloride is combined with a drug 
release controlling polymer to form an "inner" phase, which is then incorporated as 
discrete particles into an "external" phase of a second polymer. After administration, 
fluid from the gastrointestinal (GI) tract enters the tablet, causing the polymers to hydrate 
and swell. Drug is released slowly from the dosage form by a process of diffusion 
through the gel matrix that is essentially independent of ph. The hydrated polymer 
system is not rigid and is expected to be broken up by normal peristalsis in the GI tract. 
The biologically inert components of the tablet may occasionally remain intact during GI 
transit and will be eliminated in the faeces as a soft, hydrated mass.  
 
 
 
 
 
 
 
 
Fig:8 – Glucophage Wrapper  
Dissolution Data of Glucophage XR 750 
Table -5 
     Time Release 
1 HR 31 
2 HR 47 
3 HR 59 
5 HR 75 
7 HR 87 
10 HR 96 
REC 97 
                                                      1 hr     22 -   44 % 
                                                      3 hr     49  -  69% 
                                                     10 hr   NLT   85%  
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        The physical compatibility test between drug and other tablet components was 
carried out at moderate, intermediate, and extreme conditions for specified period of 
time. The mixture does not show any visible changes, this indicates that drug and other 
tablet components did not have any physical compatibility. 
 
4.3.  Evaluation of Reference Product 
  The following tests were performed for the reference product. 
a) Weight variation 
b) Thickness 
c) Hardness test 
d) Friability test 
e) Assay 
f) In-vitro Release Study 
 
a. Weight Variation 
Method: 
   Twenty tablets had been collected and individually weighed. The average weight 
and standard deviation of 20 tablets were calculated. The weight variation limits are 
given in below table. 
Table : 6  Weight variation table 
Average weight of table t (X mg) Percentage Deviation 
80 mg or less 10 
80mg to 250mg 7.5 
more than 250 mg 5 
 
b. Thickness 
Twenty tablets had been collected and each table t thickness was measured by 
using venire caliper. The allowable limit is ± 0.3%.  
 
c. Hardness 
The resistance of the tablet to chipping, abrasion or breakage under conditions of 
storage, transportation and handling before usage depends on its hardness. If the table t is 
too hard, it may not disintegrate in the required period of time and if it is too soft, it will 
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not withstand the handling during coating, packaging and shipping operations. Hardness 
was measured using hardness tester. For each batch three tablets were tested and mean 
was calculated. 
 
d. Friability 
Friability is a table t property that evaluates the ability of the table t to withstand 
abrasion in packaging, handling and shipping. 
 Twenty tablets had weighed and placed in the Roche Friabilator. Then, it was 
operated at 25 RPM for 4 minutes.  The tablets were dedusted and reweighed after 100 
revolutions. Friability of the tablets is not more than 1% of their weight. [Leon 
Lachman (1976)] 
      Initial weight - Final weight 
  % Friability =    ---------------------------------------   X 100 
                                                     Initial weight 
e. Dissolution test 
  Dissolution is the process by which a solid substance enters the solvent phase to 
yield a solution. Adequate oral bioavailability is a key pre-requisite for any orally 
administered drug to be systemically effective. Dissolution is of primary importance for 
all conventionally constructed; solid oral dosage forms in general, and can be the rate 
limiting step for absorption of drugs which are administered orally. Here the dissolution 
is performed in USB paddle apparatus and the percentage release is identified by HPLC 
method.  
 
f. Assay 
  Assay is mainly used for the determining the amount of drug content in the tablet. 
This identified by HPLC method and compared with the standard.  
 
4.4. EVALUATION OF METFORMIN HYDROCHLORIDE 
Identification Of Metformin Hydrochloride 
Description     : A   white crystal 
Solubility         : Freely soluble in water , slightly soluble in alcohol ,  
Insoluble in acetone and Dichloro methane . 
Melting Point      : 123°C 
pH                              : 6.8 IN A SOLUTION OF 1% 
Loss of drying        : Dry in vacuum at 60`c for 4 hours, it loses more than 0.5%  
Of this weight  
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4.5. Assay of Metformin Hydrochloride 
Standard Preparation: Metformin Hydrochloride working standard equivalent 
to 50 mg were taken into100ml volumetric flask and it was diluted with Methanol and 
acetonitrile and mixed. 
 
Test Preparation: Twenty tablets had taken then powdered, weight powdered 
table equivalent to 50mg metformin and transfer into 100ml volumetric flask and dilute 
with the methanol and acetonitrile. The actual drug content of Metformin layer 
containing the polymer was carried out by HPLC (High Performance Liquid 
Chromatography, 2695 waters). INERTESIC  50DS-2, 250mm length, 4.6mmID column 
and 5mm particle size. Flow rate 1.2ml per minutes, load 10, at wavelength 233mm with 
run time 15 minutes.  
 
Mobile phase – 10mM acus octain-1-sulphonic acid Na salt solution at ph3 and 
Acitonitrile at a propotion of 80:20. Injection volume -5 micro litre.  
 
4.6. Dissolution of Metformin Hydrochloride Tablets 
In vitro dissolution studies for all the compressed tablets were carried out using 
paddle method at 100 rpm in 900 ml of  6.8 pH phosphate buffer at 37°c ± 0.5°c. A 
sample was withdrawn at 1, 2, 3, 5, 7, 10 hours respectively  and is filtered through 
filters and assayed by HPLC method . An equal volume of fresh medium which was pre 
warmed at 37°c was replaced in to the dissolution medium after each sampling to 
maintain the constant volume throughout the test. 
 
Mobile Phase And Chromatographic System 
Procedure: Injected an accurately measured volume (about 5 ml) of a filtered 
portion of the solution under test in to the chromatogram by means of sampling vials. 
Record the chromatogram and measure the response of the major peak. Calculated 
metformin hydrochloride dissolved in comparisons with a standard solution having a 
known concentration of metformin hydrochloride USP in the same medium. 
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4.7. FORMULATION OF METFORMIN HYDROCHLORIDE (750mg) 
SUSTAINED RELEASE TABLETS 
Twenty formulations were prepared by wet granulation method using 5 different 
polymers in 4 different concentrations (20% , 25% , 30% , 35% ) and the formulation 
were named as  (F1 F2…….F20) . 
 
Procedure 
  The ingredients are shown in the table no - 
¾ Weigh ingredients 1,2,3 and pass through 22 sieve   
¾ Add ingredients 1 to ingredient 2 in RMG while dry mix followed by ingredient 3 
¾ Granulate the above blend using water as per parameters specified 
¾ The above granules are semi dried and are passed through cutter mill for breaking 
of lumps 
¾ The above granules are dried to get required LOD 
¾ Dried granules are passed through multi mill (cutter) and are passed through 20 
sieve 
¾ Thus obtained blend is lubricated with mg sterate (#60pass) 
¾ The above blend is compressed using 21*10mm with specified parameters  
 
 
  
Methodology
Dept.	of	Pharmaceutics,	KMCH	College	of	Pharmacy	 	44	
 
4.8. Formulation Development Trials    
Process Flow Chart     
 
                       Step: 1 
 
 
              Step: 2 
 
 
                       Step: 3 
 
  
 
                       Step: 4 
 
 
 
                       Step: 5 
 
 
                       Step: 6 
 
 
                       Step: 7 
 
  
Weighing & sieving 
Binder addition  
Mixing & granulation (RMG) 
Drying (Fluid bed drier) 
Sizing: (Sifter & Multimill) 
Blending & Lubrication  
Compression 
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4.9. Formulation Table 
Table -7 
 Formulation 
Code 
Metformin Polymer 
concentration
MCC 
pH 101 
Mg 
Ster 
Water 
(ml) 
Total 
Wt 
Methocel 
K100M  
F1 750 20% 150 5 400 1055 
F2  750 25% 112.5 5 400 1055 
F3  750 30% 75 5 420 1055 
F4  750 35% 37.5 5 450 1055 
Methocel 
 K 15M  
F5  750 20% 150 5 400 1055 
F6  750 25% 112.5 5 420 1055 
F7  750 30% 75 5 450 1055 
F8  750 35% 37.5 5 480 1055 
Methocel 
 K 4M  
F9  750 20% 150 5 400 1055 
F10  750 25% 112.5 5 440 1055 
F11  750 30% 75 5 420 1055 
F12  750 35% 37.5 5 490 1055 
Ethocel 
20 Prem  
F13  750 20% 150 5 300 1055 
F14  750 25% 112.5 5 300 1055 
F15  750 30% 75 5 300 1055 
F16  750 35% 37.5 5 300 1055 
Polyox WSR 
300 
F17  750 20% 150 5 350 1055 
F18  750 25% 112.5 5 400 1055 
F19  750 30% 75 5 440 1055 
F20 750 35% 37.5 5 310 1055 
 
Procedure  
¾ Weigh ingredients 1,2,3 and pass through 22 sieve   
¾ Add ingredients 1 to ingredient 2 in  RMG  while dry mix followed by             
ingredient 3 
¾ Granulate the above blend using water as per parameters specified 
¾ The above granules are semi dried and are passed through cutter mill for breaking 
of lumps 
¾ The above granules are dried to get required LOD 
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¾ Dried granules are passed through multi mill (cutter) and are passed through 20 
sieve 
¾ Thus obtained blend is lubricated with magnesium sterate (#60pass) 
¾ The above blend is compressed using 21*10mm with specified parameters  
 
Rapid Mixer Granulator (RMG) 
¾ Rapid mixer granulator commonly called as RMG, which is used for the 
development of granules.  
¾ It helps to determining how much amount of binder solution that we had to add.  
¾ RMG is made up of stainless steel in which the bowel which is used for adding 
the ingredients will vary in size according to the batch we are using.  
¾ Inside the bowel of RMG, there is chopper and impeller.  
¾ The water (binder) which is added to the blend with the help of a lump (in which 
RPM is settled) 
¾ The impeller will be rotating according to which RPM we setted, a continues 
action, it helps in the formation of granules.  
¾ The chopper switch is on only when the big lumps are formed (to break the 
lump).  
¾ Various parameters such as, time, impeller, chopper, amper reading is shown.  
¾ It is good to operate the RMG in a closed position.  
 
Fludised Bed Drier  
¾ Flusided bed drier is also called as FBD apparatus.  
¾ The size of the apparatus varies according to the batch size.  
¾ The FBD apparatus mainly used for reducing the water content of the granules.  
¾ Mainly we set the inlet temperature to 60°C. 
¾ The various parameters shown here are time, inlet temperature, bed temperature, 
exhaust temperature inlet and exhaust relative humidity and percentage LOD.  
¾ The operation is performed up to there is reduction in granules temperature less 
than 1.50% 
¾ In drier apparatus, there is a blower (gun) which will allow the passage of air, as 
a result the granules will be uniformly scattered and flying inside the apparatus.  
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Sonic Swifter  
¾ Sonic Swifter is mainly used for the particle size analysis.  
¾ Here there are different measures arranged in a vertical position, i.e. the order 
from #16 to 80.  
¾ These measures are arranged and packed properly.  
¾ The sample (weighed) is added to the top i.e. #16 mesh. 
¾ The vibrancy is used for 5 minutes.  
¾ Larger granules will be in the topper serve and smaller granule will be in the 
bottom.  
¾ The percentage returned is calculated by initial weight of sieve –wt after 
vibrating.  
 
4.10. Evaluations of blend (granules)45 
1. Sieve analysis. 
2. Bulk density (g/ml). 
3. Tapped density (g/ml). 
4. Hausner ratio  
5. Loss on drying. 
 
1. Sieve analysis: 
Take 100g of the dried un lubricated blend placed in the sieve shaker 
containing the mesh   #20, #30, #40, #60, #80, #100, and #200. Shake the sieve by 
using electromagnetic sieve shaker for 5 min. Weight of empty mesh was noted and 
after shaking sieve the weight of mesh with granules was noted. Then % cumulative 
release was calculated to know the % retains of granules in each mesh. 
 
2. Bulk density (g/ml): 
Bulk density is the ratio between the mass of powder and its bulk volume.  
Apparent Bulk Density was determined by pouring the weighed granules into a 
graduated cylinder via. Funnel and measuring the volume. Density was calculated 
using the formula, 
powder of eBulk volum
powder  theof Mass Density Bulk =
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 3. Tapped density (g/ml): 
           Tapped density is the ratio between a given mass of powder and its final volume 
after Tapping. It was determined by tapping a graduated cylinder containing a known 
mass of Granules for a fixed number of taps until the powder volume has reached 
minimum. The Tapped density was computed using the formula: 
powder  theof Volume Tapped
powdertheofMass Density  Tapped =
 
 
4. Carr’s Index (CI): 
  The flow ability of the granules was measured by the application of 
Compressibility  
Carr’s Index given by the equation: 
 I = [1 – V/ Vo] .100 
Where,  
V = Volume of the sample after tapping 
Vo = Volume before tapping 
Values of I: 
• Below 15% give rise to good flow characteristics 
• Above 25% indicate poor flow ability 
Hausner’s ratio: 
It is measurement of frictional resistance of the drug. The ideal range should be 
1.0-1.18. It is determined by the ratio of tapped density and bulk density  
Hausner’s ratio=Tapped density/Bulk density 
Flow Properties 
Table -8 
Compressibility 
Index 
Flow  
character 
Hauser ratio 
5-10 Excellent 1.00-1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.45 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
More than40 Very, Very 
poor 
More than 1.60 
Methodology
Dept.	of	Pharmaceutics,	KMCH	College	of	Pharmacy	 	49	
 
5. Loss on drying: 
 Loss on drying was done using IR Moisture Analyzer to check the moisture 
content in the blend. The LOD should be below 3% for the blend. If it was on the 
higher side it will causes the sticking and picking. 
 
 Chemical and physical characterizations of drug substance are essential before 
the formulation development. Pre formulation studies give the information needed to 
define the nature of the drug substances and provide a framework for the drug 
combination with pharmaceutical Excipients in the fabrication of a dosage form 
 
Analysis of Active Pharmaceutical Ingredient 
 The physicochemical characterization of active pharmaceutical ingredient like 
physical appearance, solubility, particle size analysis, identification test, alkalinity, loss 
on drying, impurity test and assay were performed. 
 
Pre-formulation Study 
Pre formulation studies are the first step in the rational development of dosage 
form of a drug substance. The objective of pre formulation study is to identify those 
physico-chemical properties and Excipients that may influence the formulation design, 
method of manufacture and pharmacokinetic and bio pharmaceutical properties of the 
product.  
Pre formulation can be defined as investigation of physical and chemical 
properties of drug substance alone and when combined with Excipients under specified 
storage conditions. 
 
4.11. Drug Excipients Compatibility Studies 
Selection of Excipients: 
The excipients which are being used in the reference product are selected. Apart 
from the excipients listed in the reference product, other excipients are also considered 
based on the possible use of them. 
 
Method: The drug – excipients mixture was prepared in the duplicate ratio as 
mentioned in   table number 9. The mixtures were filled into EP type I glass vials, sealed 
with rubber closures and aluminum caps, and subjected to accelerated condition 
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(6months in 40°C / 75 % RH), short term condition  to check any physical changes and 
related substances  level.  
 
Table -9 Drug Excipients compatibility study table 
 
S.No Exceipients  40°C/75% Rh 
6 months  
1 Metformin  - 
2 Metformin + Methocel K 100M - 
3 Metformin + Methocel K 15M - 
4 Metformin + Methocel K4M - 
5 Metformin + Ethocel 20Prem - 
6 Metformin + Polyox WSR 300 - 
7 Metformin + Methocel K 100M + K15M + 
K4M+ Ethocel 20 Prem+ Polyox WSR 300 
- 
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7. RESULTS AND DISCUSSION 
 
Innovator results  
Table -10 
 
Metformin hydrochloride was subjected to the following tests and has passed all 
the tests for identification 
 
Table -11 
TESTS FOR METFORMIN HYDROCHLORIDE 
Sl. No Test Limits as per monograph Observation 
1 Description White crystals Complies with USP 
2 Solubility Freely soluble in water , slightly 
soluble in alcohol , in soluble in 
acetone 
Complies with USP 
3 Melting point 122°C 125°C 123°C 
4 Identification IR absorption spectrum 
concordant with the reference 
spectrum 
Complies with USP 
5 Assay 95.0-98.0  
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Table -12 
 
TRIALS WITH DIFFERENT 
CONCENTRATION OF 
POLYMERS          
1.  WITH  METHOCEL K100M
FORMULAT
‐ION CODE
METFORM 
IN
METHO CEL 
K100M AT 
DIFF CONC
MCC PH 
101
Mg STER Water   
(MI)
Total wt.
F1
F2
F3
F4
750
750
750
750
150 
(20%)
187.5 
(25%)    
225 
(30%)    
262.5(3
150  
112.5
75  
37.5  
5
5
5
5
400  
400
420  
450
1055
1055
1055
1055  
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Table -13 
RMG PARAMETERS FOR F1 
EX.NO :1 
PUMP RPM:70 rpm 
BOWEL CAPACITY  .5 lit  
TIME 
(HH:MM)  
     STEP  BINDER 
QUANTITY  
IMPELLER/ 
AMP  
CHOPPER/ 
AMP  
OBSERVATION  
10:00  DRY MIX       _  200/1.8‐1.9    _  UNI MIX  
2:00  BINDER ADD    150  150/1.8    _  PAR WET OF BL 
2:00  KNEADING    _    200/1.8    _   
3:00  KNEADING   _   200/1.8   2250/0.7  UNI DIST  
2:00  BINDER ADD    150    150/1.8     _  WETT OF BLEN  
2:00  KNEADING    _    200/1.8    _    _  
 3:00    KNEADING    200/1.8    2250/0.7  UNI DIS  
2:00  BINDER ADD   100     150/1.8    _    _  
2:00   KNEADING    _     200/1.8   _    _  
5:00  KNEADING  _   200/1.8           2880/0.7  OPT GRNU OB  
5:00  KNEADING   _    200/1.8            2880/0.7  SLI OVER GRA  
 
Table -14 
RMG PARAMETERS OF F2 
EX.NO:2 
PUMP RPM:70 
BOWEL CAPACITY.5lit  
   
TIME  
   STEP  BINDER 
QUANTITY  
IMPELLER/ 
AMP  
CHOPPER/ 
AMP  
OBSERVATION  
10:00  DRY MIX        _  200/1.8‐1.9    _  UNI MIX  
2:00  BINDER ADD    150  150/1.8   _  PAR WET OF BL  
2:00  KNEADING    _   200/1.8   _   
3:00  KNEADING    _   200/1.8   2250/0.7  UNI DIST  
2:00  BINDER ADD    150   150/1.8    _  WETT OF BLEN  
2:00  KNEADING    _   200/1.8   _    _  
 3:00    KNEADING    200/1.8    2250/0.7  UNI DIS  
2:00  BINDER ADD   100    150/1.8   _    _  
2:00   KNEADING    _    200/1.8  _    _  
5:00  KNEADING   _   200/1.8                 2880/0.7  OPT GRNU OB  
5:00  KNEADING   _   200/1.8                 2880/0.7  SLI OVER GRA  
Results	&	Discussion
Dept.	of	Pharmaceutics,	KMCH	College	of	Pharmacy	 	64	
 
Table -15 
RMG PARAMETERS OF F3
EXP.NO. 3
PUMP RPM ‐ 40
BOWEL CAPACITY .5 lit
TIME STEP BINDER 
QUANTITY
IMPELLER/ AMP CHOPPER/ 
AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _ PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00 KNEADING _ 200/1.8 2250/0.7 UNI DIST
2:00 BINDER ADD 150 150/1.8 _ PARTIALWETTING OF 
BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 120 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ _
5:00 KNEADING _ 200/1.8                 2880/0.7 OPT GRNU OB
5:00 KNEADING _ 200/1.8                 2880/0.7 SLI OVER GRA
 
 
Table -16 
RMG PARAMETERS OF F4
EXP.NO: 4
PUMP RPM: 40
BOWEL CAPACITY .5 lit
TIME STEP BINDER 
QUANTITY
IMPELLER/ AMP CHOPPER/ 
AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _ NO WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00 KNEADING _ 200/1.8 PARTIAL DIST
2:00 BINDER ADD 150 150/1.8 _ PARTIALWETTING OF 
BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 150 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ _
5:00 KNEADING _ 200/1.8                 2880/0.7 OPT GRNU OB
5:00 KNEADING _ 200/1.8                 2880/0.7 SLI OVER GRA
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Discussion of RMG Parameters (F1-F4) 
¾ According to all the parameters evaluation, the time consumption for all the 
formulation (F1….F4) is the same 38 minutes.  
¾ Good granule were formed, the physical observation that inside the bowel, the 
flow of granule is like the water flow from a pipe.  
¾ For F1 and F2 the binding consumption is same (400ml) and Four F3 and F4 the 
binder consumption vary from 420 and 450ml.  
¾ Slight sticky to the side of the bowel observed.  
¾ Big lumps formed, so frequent operation of chopper needed.  
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Table -17 
FBD PARAMETERS OF F1
BATCH NO: 1
BLOWER SPEED 40Hz
SET TEMP 60°C
TIME        
(MIN)
TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0
10
20
30
40
50
58
59
58
57
59
60
24
24
24
43
47
48
32
33
33
35
39
37
40
42
43
70
39
34
39
35
27
31
25
48
15.53
6.53
5.35
1.15
RACKING
Bag
suction
 
 
Table -18 
FBD PARAMETERS OF F2
BATCH NO: 2
BLOWER SPEED 40Hz
SET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0  
10  
20  
30  
40  
50 
58
58
59
59
60
60
24
24
26
41
48
49
32
33
34
35
38
39
42
43
50
52
35
36
38
36
30
41
43
49
15.5
5.89  
5.30 
1.30 
racking
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Table -19 
FBD PARAMETERS OF F3
BATCH NO: 3
BLOWER SPEED 40Hz
SET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
10   0  
20  
30  
40  
50 
58
52
55
59
59
60
25
26
29
35
42
53
35
39
37
40
43
45
40
39
37
36
32
31
36
38
35
41
45
52
16.25
10.10
4.25
1.3  
 
 
Table -20 
FBD PARAMETERS OF F4
BATCH NO: 4
BLOWER SPEED 40Hz
SET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0  
10  
20  
30  
40  
50
49
50
53
55
58
60
21
25
30
35
43
50
34
39
41
43
45
49
45
42
36
34
32
31
36
39
35
41
46
53
16.25
10.10
4.25
1.30
Bag suction
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Discussion of FBD Parameter (F1-F4) 
¾ The time consumed for the whole process is 50 minutes.  
¾ The inlet temperature varies for all the formation varies from 58-60.  
¾ All the formulation we got at 50 minutes the percentage LOD is less than 1.50 
¾ Free flow of granules inside the apparatus.  
¾ Uniform distribution of temperature for granules. 
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PARTICLE SIZE ANALYSIS 
Table -21 
For F 1
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.8 1.8 %
2 #16‐18 8.9 10.7 %
3 #18‐20 13.9 24.6 %
4 #20‐30 18.5 43.1 %
5 #30‐60 22.7 65.8 %
6 #60‐80 25.8 91.6 %
7 #80 PASS 8.4 100 %  
 
Table -22 
 
FOR F2
SL.NO SIEVE NO % RET COMM
1
2
3
4
5
6
7
#16
#16‐18
#18‐20
#20‐30
#30‐60
#60‐80
#80 PASS
2.7
9.0
8.3
10.3
17.3
5.3
47.2
2.7%
11.6%
19.9%
30.2%
47.5%
52.8%
100%  
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Table -23 
FOR F3
SL.NO SIEVE NO % RET COMM
1
2
3
4
5
6
7
#16
#16‐18
#18‐20
#20‐30
#30‐60
#60‐80
#80 PASS
3.5
9.3
9.6
10.2
17.9
5.2
47.9
2.8%
11.8%
19.7%
30.4%
47.7%
52.7%
100%  
 
 
Table -24 
FOR F4
SL.NO SIEVE NO % RET COMM
1
2
3
4
5
6
7
#16
#16‐18
#18‐20
#20‐30
#30‐60
#60‐80
#80 PASS
3.1
9.6
9.8
10.5
17.8
5.7
47.8
3.0%
12.1%
19.8%
30.5%
49.7%
53.7%
100%  
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Table -25 
COMPRESSION PARAMETERS 
PUNCH 
SIZE
TABLET 
wt %
ACTUAL
wt
TABLET  
THICK
TABLET 
HARDNE
SS
TURR
ET 
rpm
FRIAB
ILITY
TD BD HR FLOW
F1
2 1*10M
1055 1040‐1060 5.39‐5.43 15.96‐16.30 6 0.58 0.52 0.42 1.23 FAIR‐
VIB
F2 
21*10
M
1055 1040‐
1060
5.40‐
5.45
15.98‐
16.35
6 0.58 0.51 0.43 1.18 GOO
D‐
NOT 
ARC
F3 
21#10
M
1055 1037‐
1041
5.37‐
5.41
15.97‐
16.32
6 0.60 0.51 0.41 1.24 FAIR 
VIB
F4 
21*10
M
1055 1041‐
1047
5.36‐
5.39
15.60‐
15.97
6 0.59 0.62 0.53 1.16 GOO
D 
NOT 
ARC  
 
 
 
Table -26 
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Fig:9 Dissolution Graph of Methocel K100M 
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Discussion  
• All the parameters thickness, hardness, friability were satisfactory as compared 
with innovator. 
• But the dissolution is found to be varying as compared with innovator. 
• For F1 – At the 1st and the 10th hour the release falls within the limit.3rd hour the 
release is so fast. 
• For F2-- At the 1st and the 10th hour the release falls within the limit.3rd hour the 
release is so fast. 
• For F3—1st hour the release is in border 3rd hour the Release is so fast.10th hour 
falls within the limit. 
• For F4—1st and 3rd hour release is high.10th hour the release is satisfactory. 
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Table -27 
2. WITH METHOCEL K15M
FORMULAT
ION CODE
METFORMIN METHO CEL 
K15 M
MCC PH  
101
MG STER H2O TOTAL wt
F5 750 150
(20%)
150   5 400 1055
F6 750 187.5
(25%)
112.5 5 420 1055
F7 750 225
(30%)
75 5 450 1055
F8 750 262.5
(35%)
27.5 5 480 1055
 
 
Table -28 
RMG PARAMETERS FOR F5
EX NO: 5
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _ PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00   
2:00
KN EADING 
KNEADING
_  
‐
200/1.8 
200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 150 150/1.8 _ WETT OF BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 100 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ _
5:00 KNEADING _ 200/1.8                 2880/0.7 OPT GRNU OB
5:00 KNEADING _ 200/1.8                2880/0.7 SLI OVER GRA
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Table -29 
RMG PARAMETERS FOR F6
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/A
MP
OBSERVATION
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _ PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00   
2:00
KN EADING 
KNEADING
_  
‐
200/1.8 
200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 150 150/1.8 _ SLIGHT WETT OF 
BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 120 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ _
5:00 KNEADING _ 200/1.8                 2880/0.7 OPT GRNU OB
EX NO: 6
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
 
 
 
 
Table -30 
RMG PARAMETERS FOR F7
TIME 
(HH:MM)
STEP BINDER 
ADDITIO
N
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _  PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00   
2:00
KN EADING 
KNEADING
_  
‐
200/1.8 
200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 150 150/1.8 _ SLIGHT WETT OF BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 120 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ NOT OPT GRAULES
2:00
3;00
BINDER ADD
KNEADING
30 150/1.8
200/1.8
_
2250/0.7
‐
OPT GRNU OB
5:00 KNEADING _ 200/1.8                 2880/0.7 SLI OVER GRA
EX NO: 7
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
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Table -31 
 
RMG PARAMETERS FOR F8
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _  PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00   
2:00
KN EADING 
KNEADING
_  
‐
200/1.8 
200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 150 150/1.8 _ SLIGHT WETT OF BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 120 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ NOT OPT GRAULES
2:00
3;00
BINDER ADD
KNEADING
60 150/1.8
200/1.8
_
2250/0.7
‐
OPT GRNU OB
5:00 KNEADING _ 200/1.8               2880/0.7 SLI OVER GRA
EX NO: 8
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
 
 
 
 
Discussion on RMG Parameters (F5-F8) 
¾ According to all the parameters evaluation, the time consumption for all the 
formulation (F5 to F8) as the same, i.e. 40 minutes.  
¾ Good granules were formed, at 40 minutes, the blend just flow like a water flow 
from pipe.  
¾ The binder consumption varies from F5-F8 i.e. 400-480ml.  
¾ There is no sticking to the bowel.  
¾ There is no lumps formation.  
¾ Here there is frequent kneading required.  
¾ The impeller parameter is frequently fluctuating.  
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Table -32 
FBD PARAMETERS OF F5
BATCH NO: 5 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0 55 26 32 34 44 15.37
10 58 27 34 36 41 RACKING
20 60 33 34 38 30 11.21
30 57 40 34 39 37 9.36
40 60 36 32 38 35
50 60 45 37 38 30 1.50
BLOWER SPEED 40Hz
 
 
Table -33 
FBD PARAMETERS OF F6
BATCH NO: 6 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0 54 23 29 31 39 15.37
10 55 26 32 35 40 Bag  
suction
20 60 31 34 38 43 10.34
30 57 38 35 38 38 5.54
40 60 39 37 39 36
50 60 40 38 39 32 1.34
BLOWER SPEED 40Hz
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Table -34 
FBD PARAMETERS OF F7
BATCH NO: 7 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0 56 29 33 35 45 12.67
10 57 30 35 38 42
20 59 28 37 39 30 9.65 RACKING
30 58 32 36 42 35 4.89 Bag 
suction
40 59 35 38 39 36
50 60 37 40 38 30 1.20
BLOWER SPEED 40Hz
 
 
 
Table -35 
FBD PARAMETERS OF F8
BATCH NO: 8 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0 58 25 35 40 36 16.25
10 52 26 39 39 38 Racking
20 55 29 37 37 35
30 59 35 40 36 41 10.10
40 59 42 43 32 45 4.25
50 60 53 45 31 52 1.3
BLOWER SPEED 40Hz
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Discussion on FBD Parameters (F5-F8) 
¾ Here the blower speed set for 40Hz. 
¾ The inlet temperature is set for 60°C 
¾ The time consumed for the whole process is 50 minutes.  
¾ The inlet temperature 56-60. 
¾ The bed temperature ranges from 23-45.  
¾ All the formulation we got at 50 minutes the percentage LOD is less than 1.50.  
¾ Free flow of granules inside the apparatus.  
¾ Bag suction is frequently needed.  
¾ Temperature is uniformly distributed to granules.  
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Table -36 
PARTICLE SIZE ANALYSIS FOR F5
SL.NO SIEVE NO % RET CUMULATIVE
RELEASE
1 #16 1.0 1.0
2 #16‐18 8.9 9.9
3 #18‐20 9.2 19.1
4 #20‐30 13.9 33.0
5 #30‐60 26.4 59.0
6 #60‐80 6.9 66.3
7 #80 PASS 33.7 100%  
 
 
Table -37 
PARTICLE SIZE ANALYSIS FOR F6
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.3 1.3 %
2 #16‐18 3.1 4.4 %
3 #18‐20 9.7 14.1 %
4 #20‐30 15.7 29.8 %
5 #30‐60 23.7 53.5 %
6 #60‐80 16.6 70.1 %
7 #80 PASS 31.6 100  %  
 
 
  
Results	&	Discussion
Dept.	of	Pharmaceutics,	KMCH	College	of	Pharmacy	 	80	
 
Table -38 
 
PARTICLE SIZE ANALYSIS FOR F7
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.7 1.7 %
2 #16‐18 5.9 7.6 %
3 #18‐20 12.5 20.1 %
4 #20‐30 16.5 36.6 %
5 #30‐60 24.6 61.2 %
6 #60‐80 20.3 81.5 %
7 #80 PASS 30.5 100 %  
 
 
Table -39 
PARTICLE SIZE ANALYSIS FOR F8
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 2.1 2.1 %
2 #16‐18 8.1 10.2 %
3 #18‐20 12.8 23 %
4 #20‐30 19.6 42.6 %
5 #30‐60 25.7 68.3 %
6 #60‐80 20.7 89 %
7 #80 PASS 33.6 100 %  
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Table -40 
COMPRESSION PARAMETERS 
PUNCH 
SIZE
TABLET 
wt %
ACTUAL
wt
TABLET  
THICK
TABLET 
HARDN
ESS
TARRET 
rpm
FRIAB
ILITY
TD BD HR FLOW
F5
2 1*10M
1055 1040‐
1066
5.10‐
5.30
14.39‐
16.10
6 0.60 0.50 O.4
2
1.19 FAIR 
VIB
F6 
21*10
M
1055 1043‐
1061
5.15‐
5.40
14.30‐
16.20
6 0.63 0.51 0.42 1.21 FAIR 
VIB
F7 
21#10
M
1055 1040‐
1060
5.20‐
5.50
14.00‐
16.20
6 0.62 0.52 0.42 1.23 FAIR 
VIB
F8
21*10
M
1055 1045‐
1065
5.13 14.35‐
16.30
6 0.67 0.61 0.52 1.71 GOO
D 
NOT 
ARC  
 
Table -41 
DISSOLUTION DATA
TIME IN HOURS FORMULATIONS
F5 F6 F7 F8
1 37
……
49 37
……
31
…..
2 48 67 53 39
3 70 79 70
=
51
…..
5 71 84 72 51
7 80 90 82 65
10 84 92
……
82 82
REC 90 108 91 112
Assay  98 98 99 99  
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Fig:10 Dissolution Graph of Methocel K15M 
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Discussion  
• For F5—1st hour and the 10th hour the release is satisfactory.3rd hour the release 
is slightly high. 
• For F6– 1st and the 3rd hour is high.10th hour the release is up to limit. 
• For F7– 1st and 3rd hour the release is moderate.10th hour the release is very slow 
that is less than 85%. 
• For F8 – 1st and 3rd hour the release is moderate.10th hour the release is very slow. 
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Table -42 
3.WITH METHOCEL K4M
FORM 
CODE
METFORM METHOCEL
K4M
MCC PH 
101
MG STER WATER TOTAL wt
F9 750 150
(20%)
150 5 400 1055
F10 750 187.5
(25%)
112.2 5 440 1055
F11 750 225
(30%)
75 5 420 1055
F12 750 262.5
(35%)
37.5 5 490 1055
 
 
Table -43 
RMG PARAMETERS FOR F9
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _ PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00 KNEADING _ 200/1.8 2250/0.7 UNI DIST
2:00 BINDER ADD 150 150/1.8 _ WETT OF BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 100 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ _
5:00 KNEADING _ 200/1.8                 2880/0.7 OPT GRNU OB
5:00 KNEADING _ 200/1.8                 2880/0.7 SLI OVER GRA
EX NO:
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
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Table -44 
RMG PARAMETERS FOR F10
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _  PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00   
2:00
KN EADING 
KNEADING
_  
‐
200/1.8 
200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 150 150/1.8 _ SLIGHT WETT OF BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 140 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ NOT OPT GRAULES
3;00 KNEADING 200/1.8 2250/0.7 OPT GRNU OB
5:00 KNEADING _ 200/1.8                 2880/0.7 SLI OVER GRA
EX NO: 10
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
 
 
Table -45 
RMG PARAMETERS FOR F11
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _  PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00   
2:00
KN EADING 
KNEADING
_  
‐
200/1.8 
200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 150 150/1.8 _ SLIGHT WETT OF BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 120 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ NOT OPT GRAULES
2:00
3;00
BINDER ADD
KNEADING
30 150/1.8
200/1.8
_
2250/0.7
‐
OPT GRNU OB
5:00 KNEADING _ 200/1.8             2880/0.7 SLI OVER GRA
EX NO: 11
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
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Table -46 
RMG PARAMETERS FOR F12
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _  PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00   
2:00
KN EADING 
KNEADING
_  
‐
200/1.8 
200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 150 150/1.8 _ SLIGHT WETT OF BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 120 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ NOT OPT GRAULES
2:00
3;00
BINDER ADD
KNEADING
60 150/1.8
200/1.8
_
2250/0.7
‐
OPT GRNU OB
5:00 KNEADING _ 200/1.8          2880/0.7 SLI OVER GRA
EX NO: 12
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
 
 
 
Discussion on RMG Parameters for F9 to F12 
¾ According to all the parameters evaluation the time consumption for all the 
formulation (F9-F12) is not uniform.  
¾ For F9 & F10 it is 38 minutes and F11 & F12 it is 40 minutes.  
¾ Good granules were formed.  
¾ The binder consumption varies from 400 to 490ml.  
¾ Big lumps formed, chopper operation needed.  
¾ Especially for F11 the kneading time increases.  
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Table -47 
FBD PARAMETERS OF F9
BATCH NO: 9
BLOWER SPEED 40Hz
SET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0  
10  
20  
30  
40  
50 
58
58
59
59
60
60
24
24
26
41
48
49
32
33
34
35
38
39
42
43
50
52
35
36
38
36
30
41
43
49
15.5
5.89  
5.30 
1.30 
racking
 
 
Table -48 
FBD PARAMETERS OF F10
BATCH NO: 10 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
10 
0
20  
30  
40  
50 
58
52
55
59
59
60
25
26
29
35
42
53
35
39
37
40
43
45
40
39
37
36
32
31
36
38
35
41
45
52
16.25
10.10
4.25
1.3
Bag
suction
BLOWER SPEED 40Hz
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Table -49 
FBD PARAMETERS OF F11
BATCH NO: 11
BLOWER SPEED 40Hz
SET TEMP 60°C
TIME        
(MIN)
TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0  
10  
20  
30  
40  
50 
58
59
58
57
59
60
24
24
24
43
47
48
32
33
33
35
39
37
40
42
43
70
39
34
39
35
27
31
25
48
15.53
6.53
5.35
1.15
RACKING
 
 
Table -50 
FBD PARAMETERS OF F12
BATCH NO: 12 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
10    
0
20  
30  
40  
50 
58
52
55
59
59
60
25
26
29
35
42
53
35
39
37
40
43
45
40
39
37
36
32
31
36
38
35
41
45
52
16.25
10.10
4.25
1.3
RACKING
BLOWER SPEED 40Hz
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Discussion on FBD Parameters  
¾ Blower speed is 40 Hz. 
¾ Inlet temperature 60°C. 
¾ Inlet temperature varies from 58 to 60 and of bed temperature is from 24 to 48.  
¾ The time consumption for whole process is 50minutes.  
¾ The percentage of LOD we got within 50minutes is less than 1.50.  
¾ Here we observed that the granules settled at the bottom.  
¾ The granules were so hard.  
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Table -51 
PARTICLE SIZE ANALYSIS FOR F9
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.4 1.4 %
2 #16‐18 6.3 7.7 %
3 #18‐20 11.3 19 %
4 #20‐30 17.8 36.7 %
5 #30‐60 21.5 58.3 %
6 #60‐80 16.7 75 %
7 #80 PASS 32.6 100 %  
 
Table -52 
PARTICLE SIZE ANALYSIS FOR F10
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.7 1.7 %
2 #16‐18 5.2 6.9 %
3 #18‐20 12.5 19.4 %
4 #20‐30 16.2 35.6 %
5 #30‐60 21.5 57.1 %
6 #60‐80 16.8 73.9 %
7 #80 PASS 26.1 100 %  
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Table -53 
PARTICLE SIZE ANALYSIS FOR F11
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.2 1.2 %
2 #16‐18 6.2 7.4 %
3 #18‐20 10.5 17.9 %
4 #20‐30 15.8 33.7 %
5 #30‐60 21.4 55.1 %
6 #60‐80 25.7 80.8 %
7 #80 PASS 19.2 100 %  
 
 
Table -54 
PARTICLE SIZE ANALYSIS FOR F12
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.4 1.4 %
2 #16‐18 5.9 7.3 %
3 #18‐20 11.2 18.3 %
4 #20‐30 18.9 37.7 %
5 #30‐60 25.7 63.3 %
6 #60‐80 16.9 80.3 %
7 #80 PASS 19.7 100 %  
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Table -55 
 
PUNC
H SIZE
TABLET 
wt %
ACTUAL
wt
TABLET  
THICK
TABLET 
HARD
NESS
TARRE
T rpm
FRIA
BILIT
Y
TD BD HR FLO
W
F9
2 1*10M
1055 1020‐
1059
5.30‐
5.90 
MM
12.8‐
13.6
6 0.56 0.60 0.4
9
1.22 FAIR 
VIB
F10 
21*10
M
1055 1022‐
1058
5.30‐
5.90
12.8‐
13.9
6 0.63 0.51 0.4
1
1.24 FAIR 
VIB
F11
21#10
M
1055 1020‐
1060
5.30‐
5.90
12.9‐
13.7
6 0.69 0.50 0.4
2
1.21 FAIR 
VIB
F12
21*10
M
1055 1030‐
1065
5.31‐
5.94
12.90‐
14.24
6 0.68 0.52 0.4
3
1.20 FAIR 
VIB
 
 
Table -56 
 
DISSOLUTION DATA
TIME IN 
HOURS
FORMULATIONS
F9 F10 F11 F12
1 39
….
37
….
40
….
40
…..
2 59 55 57 55
3 62
….
70
=
73 79
5 72 72 85 82
7 8O 80 95 92
10 82 83 102
…….
100
…..
REC 91 110 103 105
Assay  99 99 98 98
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Fig:11  Dissolution Graph of Methocel K4M 
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Discussion  
• For F9—1st and third hour the release is moderate.10th hour the release is very 
slow. 
• For F10—1st and 3rd hour the release is moderate and 10th hour the release is very 
slow. 
• For F11—1st and 10 hour the release is moderate but 3rd hour the release 
increases. 
• For F12-- F11—1st and 10 hour the release is moderate but 3rd hour the release 
increases 
• The granules are so hard.  
• So we go for multi mill apparatus.  
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Table -57 
4. WITH ETHOCEL 20 PREM
FORMULATION MET ETHOCEL
20 PRE
MCC PH 
101
MG STER WATER TOTAL wt
F13 750 150
(20%)
150 5 300 1055
F14 750 187.5
(25%)
112.5 5 300 1055
F15 750 225
(30%)
75 5 300 1055
F16 750 262.5
(35%)
37.5 5 300 1055
 
 
Table -58 
RMG PARAMETERS FOR F13
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _ WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00 KNEADING _ 200/1.8 2250/0.7 UNI DIST
2:00 BINDER ADD 150 150/1.8 _ OPT GRANU 
OBTAINED
2:00 KNEADING _ 200/1.8 2880/0.7 SLI OVER GRA
EX NO: 13
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
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Table -59 
 
RMG PARAMETERS FOR F14
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _ WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00 KNEADING _ 200/1.8 2250/0.7 UNI DIST
2:00 BINDER ADD 150 150/1.8 _ OPT GRANU 
OBTAINED
2:00 KNEADING _ 200/1.8 2880/0.7 SLI OVER GRA
EX NO: 14
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
 
 
Table -60 
 
RMG PARAMETERS FOR F15
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _ WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00 KNEADING _ 200/1.8 2250/0.7 UNI DIST
2:00 BINDER ADD 150 150/1.8 _ OPT GRANU 
OBTAINED
2:00 KNEADING _ 200/1.8 2880/0.7 SLI OVER GRA
EX NO: 15
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
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Table -61 
RMG PARAMETERS FOR F16
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _ WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00 KNEADING _ 200/1.8 2250/0.7 UNI DIST
2:00 BINDER ADD 150 150/1.8 _ OPT GRANU 
OBTAINED
2:00 KNEADING _ 200/1.8 2880/0.7 SLI OVER GRA
EX NO:  16
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
 
 
Discussion on RMG Parameters for F13to F16 
¾ According to all the parameters evaluation, the time consumption for all the 
formulation is very less only 21minutes.  
¾ Granules were formed, but it is not uniform granules.  
¾ The binder consumption is very less as 300ml.  
¾ At all the concentration with 300ml of water good granules were formed.  
¾ There is a not big lump.  
¾ Uniform kneading time required.  
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Table -62 
FBD PARAMETERS OF F13
BATCH NO: 13 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0  
10  
20  
30  
40  
50 
58
58
61
65
68
59
29
30
33
35
42
45
31
33
33
35
36
37
29
33
35
36
37
38
41
38
36
37
35
30
15.69
8.32
3.54
1.50
RACKING
BLOWER SPEED 40Hz
 
 
Table -63 
FBD PARAMETERS OF F14
BATCH NO: 14 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0  
10  
20  
30  
40  
50 
57
57
61
65
68
60
29
32
33
37
42
45
31
33
34
37
36
37
30
33
34
36
39
38
42
37
36
38
35
31
16.54
10.24
5.65
1.50
RACKING
BLOWER SPEED 40Hz
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Table -64 
FBD PARAMETERS OF F15
BATCH NO: 15 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0  
10  
20  
30  
40  
50 
55
57
63
65
67
60
25
35
33
38
42
44
31
31
34
39
39
39
32
33
34
35
39
38
42
35
36
36
35
31
14.98
11.24
4.35
1.30
RACKING
BLOWER SPEED 40Hz
 
 
Table -65 
FBD PARAMETERS OF F16
BATCH NO: 16 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0  
10  
20  
30  
40  
50 
58
56
62
65
67
59
25
35
33
38
42
44
33
31
37
39
39
39
31
32
34
36
38
38
45
35
36
37
35
33
13.24
10.12
3.24
1.45
RACKING
BLOWER SPEED 40Hz
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Discussion on FBD parameters for F13-F16 
¾ Blower speed is same i.e. 40Hz.  
¾ Inlet temperature 60°C. 
¾ Inlet temperature varies to 57-60°C and bed temperature from 29-45°C. 
¾ The percentage LOD is less than 1.50 within 50 minutes.  
¾ Frequency suction of bag needed.  
¾ Sticking to side of wall occurs.  
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Table -66 
PARTICLE SIZE ANALYSIS FOR F13
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.3 1.3
2 #16‐18 6.8 8.1
3 #18‐20 11.3 19.4
4 #20‐30 19.6 39
5 #30‐60 21.4 60.4
6 #60‐80 16.8 77.2
7 #80 PASS 22.8 100  
 
 
Table -67 
PARTICLE SIZE ANALYSIS FOR F14
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.7 1.7  %
2 #16‐18 5.2 6.9 %
3 #18‐20 10.3 17.2 %
4 #20‐30 12.6 29.8 %
5 #30‐60 16.6 46.4 %
6 #60‐80 20.5 66.9 %
7 #80 PASS 33.7 100 %  
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Table -68 
PARTICLE SIZE ANALYSIS FOR F15
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.8 1.8 %
2 #16‐18 8.9 10.7 %
3 #18‐20 13.9 24.6 %
4 #20‐30 18.5 43.1 %
5 #30‐60 22.7 65.8 %
6 #60‐80 25.8 91.6 %
7 #80 PASS 8.4 100 %  
 
 
Table -69 
PARTICLE SIZE ANALYSIS FOR F16
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.1 1.1 %
2 #16‐18 4.7 5.8 %
3 #18‐20 10.7 16.5 %
4 #20‐30 13.7 30.2 %
5 #30‐60 16.2 46.4 %
6 #60‐80 15.7 62.1 %
7 #80 PASS 37.9 100 %  
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Table -70 
COMPRESSION PARAMETERS 
PUNCH 
SIZE
TABLET 
wt %
ACTUAL
wt
TABLET  
THICK
TABLET 
HARDN
ESS
TARRET 
rpm
FRIAB
ILITY
TD BD HR FLOW
F13
2 1*10M
1055 1030‐
1062
5.10‐
5.30
15.25‐
16.00
6 0.53 0.61 0.41 1.48 VERY 
POOR  
AGIT
F14 
21*10
M
1055 1032‐
1045
5.73‐
5.41
15.85‐
16.39
6 0.59 0.62 0.46 1.34 BORD 
PASS 
MAT 
HANG 
UP
F15
21#10
M
1055 1040‐
1061
5.50‐
5.65
15.98‐
16.34
6 0.42 0.60 0.44 1.36 POOR 
MASS 
AGIT
F16
21*10
M
1055 1049‐
1057
5.67‐
5.96
15.65‐
15.43
6 0.45 0.60 0.48 1.24 FAIR 
VIB
 
 
Table -71 
 
DISSOLUTION DATA
TIME IN 
HOURS
FORMULATIONS
F13 F14 F15 F16
1 42
….
62 97 49
2 59 82 99 67
3 71 96 108 78
5 87 106 109 98
7 98 110 111 108
10 104
…..
111
…..
112
……
109
……
REC 106 116 110 109
Assay 99 99 98 99
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Fig:12 Dissolution Graph of Ethocel 20 Premium 
 
 
 
Discussion  
• In F13 to F16 the release is very slow at 1st and 3rd hour and 10th hour the release 
is moderate. 
• Only in case of F13 the release is satisfactory with 1st and 10th hour.  
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Table -72 
5.WITH POLYOX WSR 300
FORM 
CODE
METFORM METHOCEL
K4M
MCC PH 
101
MG STER WATER TOTAL wt
F17 750 150
(20%)
150 5 350 1055
F18 750 187.5
(25%)
112.5 5 400 1055
F19 750 225
(30%)
75 5 440 1055
F20 750 262.5
(35%)
37.5 5 310 1055
 
 
Table -73 
RMG PARAMETERS FOR F17
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _ PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00 KNEADING _ 200/1.8 2250/0.7 UNI DIST
2:00 BINDER ADD 100 150/1.8 _ VERY SLIGHT 
WETT OF BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 100 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ _
5:00 KNEADING _ 200/1.8             2880/0.7 OPT GRNU OB
5:00 KNEADING _ 200/1.8             2880/0.7 SLI OVER GRA
EX NO: 17
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
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Table -74 
RMG PARAMETERS FOR F18
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _ PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00 KNEADING _ 200/1.8 2250/0.7 UNI DIST
2:00 BINDER ADD 100 150/1.8 _ VERY SLIGHT 
WETT OF BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 150 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ _
5:00 KNEADING _ 200/1.8             2880/0.7 OPT GRNU OB
5:00 KNEADING _ 200/1.8             2880/0.7 SLI OVER GRA
EX NO: 18
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
 
 
Table -75 
 
RMG PARAMETERS FOR F19
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _  PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00   
2:00
KN EADING 
KNEADING
_  
‐
200/1.8 
200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 150 150/1.8 _ SLIGHT WETT 
OF BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 140 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ NOT OPT 
GRAULES
3;00 KNEADING 200/1.8 2250/0.7 OPT GRNU OB
5:00 KNEADING _ 200/1.8             2880/0.7 SLI OVER GRA
EX NO: 19
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
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Table -76 
RMG PARAMETERS FOR F20
TIME 
(HH:MM)
STEP BINDER 
ADDITION
IMPELLER 
SPEED/AMP
CHOPPER 
SPEED/AMP
OBSERVATION
10:00 DRY MIX _ 200/1.8‐1.9 _ UNI MIX
2:00 BINDER ADD 150 150/1.8 _  PAR WET OF BL
2:00 KNEADING _ 200/1.8 _ 
3:00   
2:00
KN EADING 
KNEADING
_  
‐
200/1.8 
200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 150 150/1.8 _ SLIGHT WETT 
OF BLEN
2:00 KNEADING _ 200/1.8 _ _
3:00 KNEADING 200/1.8 2250/0.7 UNI DIS
2:00 BINDER ADD 160 150/1.8 _ _
2:00 KNEADING _ 200/1.8 _ NOT OPT 
GRAULES
3;00 KNEADING 200/1.8 2250/0.7 OPT GRNU OB
5:00 KNEADING _ 200/1.8             2880/0.7 SLI OVER GRA
EX NO: 20
PUMP RPM : 70 rpm
BOWEL CAPACITY .5 lit
 
 
 
Discussion on RMG Parameters F17to F20 
¾ According to all the parameters evaluated the time consumption for all the 
formulation (F17-F20) is the same 38 minutes.  
¾ Good granules, formed  
¾ Uniform size granules  
¾ The physical observation that inside the bower, the flow of granules is like the 
water flow from a pin.  
¾ The binder consumption varies from 350-440ml.  
¾ No big lump formed.  
¾ Uniform kneading required.  
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Table -77 
 
FBD PARAMETERS OF F17
BATCH NO: 17 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0
10
20
30
40
50
55
56
58
57
59
60
22
24
43
47
48  
49
31
33
35
38
39
37
40
42
43
70
39
34
39
35
27
31
25
48
14.32
5.63
3.32
1.15
RACKING
BLOWER SPEED 40Hz
 
 
Table -78 
 
FBD PARAMETERS OF F18
BATCH NO: 18 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0
10
20
30
40
50
40
42
49
52
56
60
20
24
30
35
41  
49
31
36
35
39
39
37
43
42
43
34
39
34
39
35
27
31
25
48
12.12
8.97
4.56
1.15
RACKING
Bag 
suction
BLOWER SPEED 40Hz
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Table -79 
FBD PARAMETERS OF F19
BATCH NO: 19 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0
10
20
30
40
50
54
55
58
56
56
60
22
24
43
47
48  
49
36
33
35
38
39
37
40
42
46
49
49
34
35
35
27
38
25
48
15.15
10.32
5.76
1.15
RACKING
BLOWER SPEED 40Hz
 
 
Table -80 
FBD PARAMETERS OF F20
BATCH NO: 20 SET INLET TEMP 60°C
TIME TEMPERATURE RELATIVE HUMIDITY % LOD REMARK
INLET BED EXHAUST INLET  EXHAUST
0
10
20
30
40
50
50
52
58
56
56
60
20
24
37
47
44
49
36
37
38
38
38
39
48
46
49
49
36    
34
35
33
28
38
28
48
13.76
11.67
6.73
1.15
RACKING
BLOWER SPEED 40Hz
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Discussion of FBD Parameters F17 to F20 
¾ Time consumption for the whole process if 50 minutes.  
¾ The inlet temperature varies from 40-60°C and bed temperature varies from 20-
48°C.  
¾ Free flow of granules inside the apparatus  
¾ Uniform distribution of temperature in granules  
¾ The percentage LOD is less than 1.50.  
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Table -81 
PARTICLE SIZE ANALYSIS FOR F17
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.3 1.3 %
2 #16‐18 4.4 5.7 %
3 #18‐20 8.9 14.6 %
4 #20‐30 12.6 27.2 %
5 #30‐60 17.5 44.2 %
6 #60‐80 21.3 66n %
7 #80 PASS 22.6 100 %  
 
Table -82 
PARTICLE SIZE ANALYSIS FOR F18
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.4 1.4 %
2 #16‐18 4.5 5.9 %
3 #18‐20 6.8 12.7 %
4 #20‐30 12.5 25.2 %
5 #30‐60 17.8 43 %
6 #60‐80 21.6 64.6 %
7 #80 PASS 35.4 100 %  
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Table -83 
PARTICLE SIZE ANALYSIS FOR F19
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.5 1.5 %
2 #16‐18 6.1 7.6 %
3 #18‐20 8 15.6 %
4 #20‐30 13.1 28.7 %
5 #30‐60 16.7 45.4 %
6 #60‐80 20.3 65.7 %
7 #80 PASS 34.3 100 %  
 
Table -84 
PARTICLE SIZE ANALYSIS FOR F20
SL.NO SIEVE NO % RET CUMULATIVE
FREQUENCY
1 #16 1.8 1.8 %
2 #16‐18 6.5 8.3 %
3 #18‐20 10.3 18.6 %
4 #20‐30 13.5 32.1%
5 #30‐60 16.9 49 %
6 #60‐80 21.4 70.4 %
7 #80 PASS 29.6 100 %  
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Table -85 
COMPRESSION PARAMETERS
PUNCH 
SIZE
TABLET 
wt %
ACTUAL
wt
TABLET  
THICK
TABLET 
HARDN
ESS
TARRET 
rpm
FRIAB
ILITY
TD BD HR FLOW
F17
2 1*10M
1055 1074.17
‐
1075.63
6.54‐
6.95
12.9‐
13.7
6 0.69 0.53 0.46 1.15 GOO
D 
NOT 
ARC
F18
21*10
M
1055 1076.78
‐
1077.85
6.32‐
6.76
12.69‐
12.99
6 0.67 0.61 0.52 1.17 GOO
D 
NOT 
ARC
F19
21#10
M
1055 1081.23
‐
1084.67
7.01‐
7.93
13.58‐
14.1
6 0.58 O.62 0.53 1.16 GOO
D 
NOT 
ARC
F20
21*10
M
1055 1086.32
‐
1089.46
6.81‐
6.93
14.30‐
16.20
6 0.55 0.60 O.5
1
1.20 GOO
D 
NOT 
ARC  
 
Table -86 
DISSOLUTION DATA
TIME IN HOURS FORMULATIONS
F17 F18 F19 F20
1 32
……
33
‐‐‐‐‐‐
39
……
38
……
2 39 53 55 49
3 59
……
64   
‐‐‐‐‐‐‐‐
67
……
69
…..
5 67 8O
‐‐‐‐‐‐‐
82 83
7 75 88  
‐‐‐‐‐‐
92 92
10 90
…..
94  
‐‐‐‐‐‐‐
98
……..
105
……..
REC 100 96   104 104
Assay  98 98 99 99
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Fig:13 Dissolution Graph of Polyox WSR 300 
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Fig:14 Standard assay  
 
 
 
Results	&	Discussion
Dept.	of	Pharmaceutics,	KMCH	College	of	Pharmacy	 	113	
 
 
Fig:15  Sample of Assay  
 
 
 
Fig:16  Standard for Dissolution  
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Fig:17     1st HOUR OF DISSOLUTION  
 
 
 
 
Fig:18     3rd HOUR OF DISSOLUTION  
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Fig:19     10th  HOUR OF DISSOLUTION  
 
 
 
 
Discussion 
 
• All the formulations show the satisfactory release but the release is not steady.  
• For dissolution and assay by HPLC method it is identified that for assay we get 
for F19 is 99 percentage and for Dissolution we got the percentage release 98 
percentage. 
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Stability Study of F19  
 The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug products various with time under the influence of a variety of 
environmental factors such as temperature, humidity and light and to establish a retest 
period for the drug distance or a shelf life for the drug product and recommended storage 
condition. Hence the tablets were loaded at accelerated condition at 40°C/75%RH (short 
term). Samples were withdrawn at an initial , 1st  2nd 6th  month ,  and evaluated for 
colour hardness and drug release.  
Table -87 
Formulation F19   Stability Study Data 
S.No Parameters F19  
1st month 2nd month 3rd month 6th month
1 Colour  White  White  White  white 
2 Hardness  4-6 4-6 4-6 3.9 
3 Drug content (%) 99 99 98.9 98.1 
4 % cumulative 
release  
98.90 98.88 98.68 98.10 
 
Table -88 
Glucophage  XR 
S.No Parameters GLUCOHAGE XR 750 mg 
1st month 2nd month 3rd momth 6th month
1 Colour  White  White  White  white 
2 Hardness  12.7 12.7 12.5 12 
3 Drug content (%) 97.8 97.5 96.6 96.1 
4 % cumulative release  98.97 98.30 98.14 98.9 
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8. SUMMARY AND CONCLUSION  
 
 The present work was aimed at formulation and evaluation of sustained release 
metformin hydrochloride matrix tablets(750mg) with five different polymers and 4 
different concentration 20%, 25%, 30%, 35% to find out which polymer is giving a best 
sustain release.  
 
Pre formulation Study  
 The blends for formulating tablets were prepared according to the formulation 
scheme. The pre formulation study like bulk density, tapped density, angle of repose, 
Hausners ratio were done. The results obtained were within the acceptable limit and 
showing good flow property.  
 
Compatibility Study  
 Compatibility study of metformin hydrochloride and metformin with different 
polymers like Methocel K100M, Methocel K4M, Methocel K15M, Ethocel 20 premium, 
Polyox WSR 300 at short term conditions(40/75%RH) for six months were evaluated, 
there is no cake formation, liquid formation or big lumps.  
 
Formulation  
 The tablets were prepared by wet granulation method and punched with the help 
of 10 station punching machine of 19 x 21mm punch, to attain a target weight of 
1050mg. the prepared tablets were evaluated for their post compression parameters like 
diameter, thickness, hardness, friability and weight variation test. The results obtained 
were within the acceptable limit.  
 
Evaluation of Tablets  
 The compressed tablets were than evaluated for various test like hardness, weight 
variation, content uniformity, friability, etc as per the method given in USP, all the 20 
formulation passed in the test with values with the limit prescribed by the USP.  
 
Invitro Dissolution Study  
¾ Mainly done in HPLC method 
¾ The invitro dissolution studies showing that all the formulation gives a sustained 
release but it is not matching with the innovator.  
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¾ Only the F17, F18, F19, F20 matches with the innovated.  
¾ The study showed that these polymers can be effectively used as matrix material 
for the preparation of sustained release matrix tables of metformin.  
 
Stability Study  
 The chosen best formulation were kept for stability study as per ICH guideline in 
a stability chamber for a period of six month (short term) and parameters like physical 
appearance, weight variation, hardness, drug content and dissolution rate were studied at 
the end of 1st 2nd 3rd and 6th month. Study has a long shelf life.  
 
RMG Parameters  
¾ All the 20 formulations we had performed granulation with the help of RMG 
apparatus.  
¾ All the formulations has given good granules 
¾ According to the batch size vary in time 
¾ The binder consumption also varies.  
¾ In F19 the parameters are moderate and the granules formed are good.  
 
FBD Parameters  
¾ All the formulation are subjected to FBD apparatus.  
¾ In F19 formulation we get the percentage LOD less than 1.20 in 30 minutes.  
¾ The bag dumping is needed only at 25 minutes.  
¾ So F19 formulation it is easy to handling in FBD apparatus.  
 
Particle size analysis  
¾ As compressed to all formulation, the F19 had a particle size of comparable 
range.  
¾ It is detected in sonic swifter. 
¾ In F19 we got in the range of 100%. 
¾ As compared with Tapped density and Bulk density. The Hauser’s ratio we got in 
the range of 1.16, the protocols states that, have a good flow, there won’t be arc 
formation. 
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CONCLUSION 
 
From the study, it may be concluded that F19 is the best formulation and can be 
manufactured with reproducible characteristics from batch to batch to match the release profile 
with innovator product. The findings of the present study ensure the company (Suven Nishtaa 
Pharma Pvt Ltd, Pashamylaram, Patancheru Mandal, Medak Dist, Andhra Pradesh) to launch the 
product in the market in near feature.  
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